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The decades between 1960 and 1980 wit-
nessed a major change in attitudes about 
hepatic surgery. The era began with the re-
alization by a small group of investigators 
that hepatic transplantation might become a 
realistic option for patients with otherwise 
untreatable liver diseases. A ripple effect of 
research directed toward this objective was a 
better understanding of the role of portal 
blood in maintaining hepatic homeostasis as 
well as a more complete appreciation of the 
physiologic consequences of portal-systemic 
diversion procedures. The increased knowl-
edge and boldness engendered by this ex-
perience with the liver were factors in the 
standardization and extension of techniques 
of partial hepatectomy, which previously had 
too high a mortality for general use. Finally, 
the techniques of biliary tract reconstruction 
that were refined or developed as part of 
liver transplantation have made their way 
into more general use. 
This chapter describes these advances un-
der the headings of: (1) liver transplantation, 
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(2) partial hepatectomy, and (3) portal-sys-
temic diversion. Techniques of biliary tract 
reconstruction that are applicable in a variety 
of non-transplant circumstances are covered 
under liver transplantation. 
Liver Transplantation 
Experimental Beginnings. There are 2 gen-
eral approaches to transplantation of the 
liver: (1) insertion of an extra liver (auxilia11f 
homotransplantation) at an ectopiC site, and (2) 
removal of the host liver and replacement 
with a homograft (orthotopic homotransplanta-
tion). 
Auxiliary Transplantation. The first exper-
iments with whole organ liver grafting were 
carried out with the auxiliary operation in 
dogs by Welch et alY The operation, as 
originally described or slightly modified by 
later authors (Fig. 176-1), involved the trans-
plantation of an extra canine liver in the right 
paravertebral gutter or pelvis of a non-related 
mongrel recipient. The hepatic arterial sup-
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figure 176-1. Auxiliary liver transplantation in dogs 
by a modification of Welch's original technique. Note 
that the reconstituted portal blood supply is from the 
distal inferior vena cava. Cholecystoduodenostomy is 
performed. (From Starzl TE et al. Ann Surg 1964; 
160:411-39. Reproduced with permission,) 
ply was derived from the aorta or iliac artery. 
Venous inflow was provided by anastomos-
ing the distal iliac vein or inferior vena cava 
to the homograft portal vein, Outflow was 
into the proximal iliac vein or inferior vena 
cava. 
Welch l and those who followed2-5 proved 
that such livers produced bile for several days 
after transplantation but then ceased to 
function. On examination, the transplanted 
organs had histopathologic evidence of rejec-
tion. This was to be expected, as immuno-
suppressive therapy was not given. Almost 
10 years elapsed after Welch's first publica-
tion before his operation was attempted in 
immunosuppressed canine recipients. 6 ,7 Aux-
iliary homografts inserted by a modification 
of Welch's techniques into dogs being treated 
with azathioprine were much more severely 
damaged than orthotopically placed livers 
that had been provided with a normal portal 
inflow. A search for the explanation of this 
discrepancy was the beginning of hepato-
trophic physiology, the subject of the third 
section of this chapter. 
Orthotopic Transplantation. The first 
known efforts at experimental orthotopic 
transplantation of the liver (liver replace-
ment) were made by Cannon.8 The animals 
(species not stipulated) did not survive the 
operation, and the report was so brief that it 
lacked a title or a description of the methods. 
Orthotopic transplantations of the dog 
liver were initiated in 1958 by Moore and his 
associates9 and by US. IO.ll The technical prob-
lems of liver replacement and the features of 
rejection in untreated canine recipients were 
delineated.9--12 Several years later, using im-
munosuppression with azathioprinel 3--lS and 
antilymphocyte serum (ALS) or its globulin 
derivative (ALG),13,1&-19 chronic survival was 
achieved in several mongrel dogs, of which 
one lived for almost 12 subsequent years. 20 
Garnier et a1. 21 observed in 1965 that rejection 
of orthotopic pig liver homografts was mild 
in comparison with that seen in dogs. Several 
of their porcine recipients lived for long times 
without immunosuppression. Other investi-
gators promptly confirmed Garnier's 
work13,22,2) Since then, the value of the pig 
for transplantation research has been dem-
onstrated frequently. Numerous experimen-
tal studies of auxiliary and orthotopic liver 
transplantation in various species were sub-
sequently published. Some of these have 
influenced clinical practice, but none has had 
the impact of the original investigations. 
For clinical application, orthotopic trans-
plantation has been the most promising pro-
cedure. For that reason, most of the following 
remarks will pertain to this approach. 
Clinical Trials of Orthotopic Transplanta-
tion. Transplantation of a human liver was 
first attempted on March 1, 1963,14 In the 
succeeding 10 months, 6 more such opera-
tions were performed, 4 by US6,7,14 and 2 at 
other institutions. 15,26 The longest survival 
was 23 days. 
The 7 consecutive failures in 3 institutions 
led to a 3-year moratorium on clinical trials. 
The first extended survival of a human recip-
ient was achieved in 1967.17,2R The patient, a 
1 V2 year old girl with a large primary hepa-
tocellular carcinoma, lived for more than 13 
months after the procedure before dying of 
metastases, Since then, efforts at liver trans-
plantation have been persistent. 29 The yearly 
frequency of liver transplantation is shown 
in Figure 176-2. The number of transplan-
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figure 176-2. Yearly number of liver 
transplantations at the University of Col-
orado (196.3 to 1980) and the University 
of Pittsburgh (1981 to 1982). The pro-
jection of 68 transplantations for 1982 
fell short of the 82 transplantations ac-
tually performed In that year. Note that 
retransplantation has been attempted. 
(From Starzl TE et at. Hepatology 1982: 
2:614-.36. Reproduced with permission 
of the American Association for the 
Study of Liver Disease and Williams l!Jt 
Wilkins.) 
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tations in 1982 was predicted to be 68 (Fig. 
176-2); the actual total during that year was 
82. Caine and WilliamsJO•31 treated their first 
patient in 1968, and the English series has 
now grown to more than 125. Between 1968 
and 1978, other single attempts or small 
series were reported from all over the 
world. 32-44 Since 1978, several programs have 
been reopened or initiated. Series of 6 or 
more cases each have been reported or are 
in preparation from Holland,45 East Ger-
many,46 West Germany,47.48 France,49 and the 
Republic of China. so The West German 
series./8 numbers more than 50, but the results 
have not been published. 
Of 237 patients we treated through April 
1982, 112 were children and adolescents (Ta-
ble 176-1) ranging in age from 5 months to 
18 years. The 125 adults (Table 176-2) were 
19 to 68 years old. 
Indications for Orthotopic Transplanta-
tion. None of the disorders for which trans-
plantation has been attempted should be 
excluded categorically from future trials. At 
the same time, a fairly complete understand-
ing has evolved with respect to many specific 
diseases about what advice to give to pro-
spective recipients and their families, when 
and if the operation should be decided upon, 
how much risk there is of deterioration and 
death during the search for a donor organ, 
and what technical difficulties are to be an-
ticipated during the transplantation. 
Candidacy is restricted to patients who are 
less than 55 years old, who are free of extra-
hepatic infection, and who do not have an 
extrahepatic malignancy. Within this group, 
the 2 main principles in case selection con-
cern the propriety of a decision to proceed 
and the feasibility of an attempt. The propri-
ety issue had been the dominant theme be-
cause of anxiety that meaningful life might 
be foreshortened by a dangerous and unpre-
dictable surgical undertaking. 13 Our general 
guideline was that transplantation for non-
neoplastic liver disease became justifiable 
with the advent of social and vocational 
invalidism. 51 This condition usually was re-
flected in repeated hospitalizations for en-
cephalopathy, variceal hemorrhage, hepato-
renal syndrome, uncontrolled coagulation 
disorders, intractable ascites, and other com-
plications of hepatic disease. 
Houssin et al. 49 found that all of their 
patients with alcoholic cirrhosis who had 2 
or more of the complications just mentioned 
died in 1 month or less. Their study, which 
also contained data on results of tests of liver 
function, often has been cited as providing 
criteria for candidacy. However, an effort to 
develop a clinical or biochemical profile that 
can be applied generally to such heteroge-
neous liver diseases as those listed in Tables 
176-1 and 176-2 is meaningless. Instead, 
disease-specific criteria need to be developed. 
The feasibility component of patient selec-
tion has received inadequate attention. Des-
perate attempts have been made with trans-
plantation to rescue patients who were 
bleeding to death, were in Stage 4 coma, had 
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Table 176-1. INDICATIONS FOR LIVER 
TRANSPLANTATION IN PEDIATRIC PATIENTS 
(,;; 18 YEARS OLD) (FROM MARCH L 1963, 
THROUGH APRIL 1982) 
Disease 
Biliarv atresia 
Inborn metabolic errors 
Non-alcoholic cirrhosis 
Hepatocellular carcinoma 
Neonatal hepatitis 
Secondary biliary cirrhosis 
Byler's syndrome 
Congenital hepatic fibrosis 
Budd-Chiari syndrome 
"2 had Alagille's syndrome. 
tlnborn errors 
No. Cases 
62" 
21+ 
15 
3t 
3 
3§ 
2 
2 
1 
112 
Alpha-I-antitrypsin deficiency 13 
Wilson's disease 3 
Tyrosinemia 2 
Type I glycogen storage disease 1 
Type IV glycogen storage disease 1 
Sea-blue histiocyte syndrome 1 
21 
tSeven other patients had incidental malignancies (6 
hepatocellular carcinoma and 1 hepatoblastoma) in their 
excised livers. The principal diagnoses in these 7 cases 
were biliary atresia (3 examples), congenital tyrosinemia 
(2 examples), alpha-I-antitrypsin deficiency (1 example), 
and sea-blue histiocyte syndrome (1 example), The di-
agnOSis of the neoplastic change was known in advance 
in 4 of the 7 cases. 
§Secondary to choledochal Cyst (2 examples) or trauma 
(1 example). 
anuria, or had lung fields made opaque by 
pneumonitis or pulmonary edema. This re-
flected the lateness of referral in some cases; 
in others, the patients were vital candidates 
early on but deteriorated during work-up or 
during the search for a liver donor. The 
compassion and affection for the candidates 
by the medical and surgical staffs caring for 
them during this period of physical and men-
tal decay created an almost irresistible com-
pulsion to proceed when an organ finally 
arrived, despite hopeless metabolic and tech-
nical conditions. 
Aside from the medical state of the patient, 
the question of technical feasibility also must 
receive increased attention. We have learned 
from experience that transplantation is rela-
tively easy for some hepatic diseases and 
exceptionally difficult on the average for oth-
ers. Whatever the underlying diagnosis, pa-
tients who have had earlier adhesion-forming 
operations in the upper abdomen have an 
increased perioperative mortality,29 especially 
if the porta hepatis has been dissected for 
portal diversion procedures or biliary tract 
reconstruction. 
Earlier, a devastating finding in almost 10% 
of operations was a thrombosed or hypoplas-
tic portal vein. All candidates must be stud-
ied with ultrasonography to rule out this 
possibility. When the results are equivocal, 
portal venograms are obtained after superior 
mesenteric arteriography or by transhepatic 
techniques (Fig. 176-3). Despite these pre-
cautions, errors regarding portal vein anat-
omy continue to be made. 
The work-up performed at the University 
of Pittsburgh29,52 includes confirmation of the 
prior diagnosis, analysis of residual liver 
function, measurement of the recipient's in-
tellectual and psychiatriC state, assessment 
of abnormalities of extrahepatic organ sys-
tems, and determination, insofar as possible, 
of whether liver replacement will be anatom-
ically possible. The mass of resultant data is 
considered at a weekly conference attended 
by physicians and surgeons of all specialties, 
psychologists, nurses, social workers, and 
lawyers. In the final decision, the questions 
of propriety and feasibility increasingly have 
been influenced by the nature of the hepatic 
disorder and by the difficulties or advantages 
Table 176-2. INDICATIONS FOR LIVER 
TRANSPLANTATION IN ADULT PATIENTS (> 18 
YEARS OLD) (FROM MARCH 1. 1963, THROUGH 
APRIL 1982) 
Disease 
\I on-alcoholic cirrhosis 
Primary malignancy 
Alcoholic cirrhosis 
Primary biliary cirrhosis 
Sc1eros'ing ch~langitis 
Secondary biliary cirrhosis 
Alpha-I-antitrypsin deficiency 
Budd-Chiari syndrome 
Acute hepatit{s B 
Adenomatosis 
Hemochromatosis 
Proto porphyria 
No. Cases 
47 
24"t 
15 
12 
10 
6t 
4 
3 
1 
I" 
1 
1 
125 
"One patient in each group had previous (1 and 41/2 
years earlier) right hepatic trisegmentectomy, At trans-
plantation, the regenerated left lateral segment was 
replaced with a whole liver. 
tThirteen hepatocellular carcinomas, 7 duct cell car-
cinomas (Klatskin), 2 cholangiocarcinomas, 1 heman-
gioendothelial sarcoma, 1 unclassified sarcoma. 
tTwo examples each of choledochal cyst and trauma; 
1 example each of duct hypoplasia and Caroli's syn-
drome. All 6 patients had had previous multiple opera-
tions. 
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figure 176-3. Hypoplastic portal vein (.35-mm diam-
eter) demonstrated by transhepatic portography. The 
patient was 55 years old. PV = portal vein; CV = 
coronary vein; SV = splenic vein. 
encountered with specific diseases that have 
been clarified by hard experience (Table 176-
3). 
Non-Alcoholic Cirrhosis. Sixty-two pa-
tients with this diagnosis have come to trans-
plantation; 47 were adults (Table 176-2) and 
15 were adolescents (Table 176-1). Experi-
ence has taught the urgency with which each 
candidacy must be viewed. In our entire 
experience, no patient with non-alcoholic cir-
rhosis who was accepted for transplantation 
and for whom the procedure was not carried 
out has lived for more than a few months. 
Referral for consideration of transplantation 
usually was late, but in several cases our own 
judgment was that deterioration was not yet 
severe enough to preclude proceeding in 
spite of jaundice and manifold evidence of 
inadequate hepatic function. Such dilatory 
tactics, or even the inability to find a liver 
donor promptly after a decision to go forward 
was reached, often have borne bitter fruit. 
Further hepatic decompensation usually has 
been swift, leading to coma, anuria, lethal 
bleeding into the gastrointestinal tract and 
elsewhere, and multiple infections. Many of 
the patients who eventually had transplan-
tation have required prolonged ventilatory 
support and renal dialysis before coming to 
the operating room, and the few survivors 
in this unfavorable subgroup usually have 
required the same care for long periods af-
terwards. 
The technical difficulties in replacing the 
livers of these patients may be extraordinary 
(Table 176-3). Because the livers are predict-
ably shrunken, a donor with a smaller stature 
than that of the recipient must be found. 
Otherwise, closing the incision may be im-
possible. Without previous abdominal oper-
ations, the main structures of the hepatic 
hilum are relatively normal except for the 
presence of collaterals. However, the hepatic 
veins at the upper part of the liver are so 
distorted by fibrosis and so surrounded with 
collaterals that special techniques often are 
required to develop an outflow cuff of vena 
cava (see section on surgical technique). Col-
laterals inferior to the liver are of huge size. 
Even though ties are placed on every bit of 
tissue that is cut, perfect hemostasis can 
never be achieved until the hypertensive por-
tal system is decompressed through the new 
liver, after which the second vital factor of 
improved coagulation can be expected within 
a few hours if a well preserved liver has been 
transplanted. 
The legendary marathon operations with 
dozens or even hundreds of units of blood 
transfused are commonplace in these pa-
tients. The adhesions from previous abdom-
inal operations other than portal-systemic 
shunts may create so many additional friable 
collaterals that there is little chance of suc-
ceeding. The largest blood loss ever incurred 
in a patient who survived was 110 liters. The 
recipient returned to his university depart-
mental chairmanship several months later, 
but only after spending the preoperative pe-
riod and the first 2 postoperative months on 
a ventilator. 
The technical problems in patients with 
previous portal-systemic shunts have been 
different but no less trying. Although the 
massive collaterals involute in proportion to 
the effectiveness of the shunt, the perihepatic 
area and hepatic ligaments usually are full of 
troublesome fine arterial collaterals. With loss 
of the venous collaterals, many such patients 
have cardiovascular collapse during occlu-
sion of the interconnected portal and inferior 
vena caval systems (obligatory during the 
anhepatic phase). The patient may require 
veno-venous bypass during the anhepatic 
phase to survive the insult of the reduced 
venous return to the heart. If the portal 
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Table 176-3. METABOLIC, OPERATIVE, AND OTHER FEATURES OF SPECIFIC DISEASES IN 237 
LIVER TRANSPLANTATION RECIPIENTS 
Decision about 
No. Propriety of 
Disease Cases Transplantation 
Non-alcoholic cirrhosis 62 Previously 
difficult until 
moribund, 
easier now 
Biliary atresia 62 Easy 
Hepatic malignancy 27 Easy at first, 
difficult now 
Inborn metabolic errors 25 Easy until now 
Alcoholic cirrhosis 15 Difficult 
Primary biliary cirrhosis 12 Relatively easy 
Sclerosing cholangitis 10 Relativelv 
difficult 
Secondary biliary 9 Easy 
cmhosis -
Budd-Chiari syndrome 4 Relatively 
difficult 
Neonatal hepatitis 3 Easy 
Congenital hepatic 2 Easy 
fibrosis 
Byler's syndrome 2 Easy 
Hemochroma tosis Easv 
Protoporphyria Easv 
Adenomatosis Easy 
Acute hepatitis B Difficult 
diversion has been with a portacaval shunt, 
the anastomosis must be taken down in order 
to revascularize the homograft; 2 patients 
have bled to death when portal veins were 
found to be too sclerotic to be sutured. When 
portal diversion has been with a mesocaval 
or splenorenal shunt, the shunt must be 
closed surgically to prevent the "steal" that 
would otherwise partially deprive the new 
liver of a vital component of its blood supply. 
Lethal recurrence in the homograft of the 
disease that destroyed the native liver has 
been well documented in patients with pre-
operative HBs antigenemia.29.53.54 The antigen 
titer in the best studied patient was tempo-
rarily reduced after operation, indicating that 
the excised liver was the principal but not 
the sole reservoir of the virus. 53 Complete 
clearing of the virus perioperatively was 
achieved in only' 1 of 5 recipients; in the 4 
who survived operation, the HBs antigen 
returned to high titer within a few weeks 
despite treatment with standard quantities of 
Incidence 
of Prior Usual 
Abdom- Average Metabolic 
inal Technical Abnormal- Disease 
Surgery Difficulty ities Recurrence 
52% Extreme Severe Usual with 
HBsAg 
100% Easy to Moderate None 
extreme 
96% Easy to Minimal to Common 
moderate moderate 
24% Easy to Moderate to None 
moderate severe 
13% Extreme Severe Unknown 
58% Easy Moderate to Has been 
severe described 
90% Moderate to Moderate to None, but 
extreme severe unknown 
100% Extreme Moderate to None 
severe 
75% Moderate Moderate to Has been 
severe described 
33% Easy to Severe None 
moderate 
50% Moderate Severe None 
50% Easy Moderate to ~one 
severe 
100% 
l00o/c 
100% 
0% 
hyperimmune globulin immediately postop-
eratively. Two patients died of liver failure 
after 5 months and 1411z months, respec-
tively, and a third has poor graft function 
after 13 months. Recurrent chronic aggres-
sive hepatitis was present in each case. A 
course of preoperative immunization with 
HBsAg vaccine is planned in future patients 
to stimulate an antibody response before the 
advent of immunosuppression, and immu-
noglobulin will be administered in much 
larger doses. Johnson et al. 55 of Cambridge, 
England, achieved long-term clearing of the 
antigen with globulin therapy after trans-
plantation in a patient with primary cancer. 
Nevertheless, the English team considers 
hepatitis B antigenemia a contraindication to 
transplantation. 50 
Recurrence of disease in patients with 
chronic aggressive hepatitis complicated by 
cirrhosis who do not have HBsAg has not 
been described, but such an eventuality 
would not be surprising. The potentially ad-
.3404 The Liver 
verse role of recurrence coupled with the 
enormous difficulty of the operation could 
lead to a decision against treating patients 
with underlying chronic aggressive hepatitis. 
In fact, continued efforts to treat non-alco-
holic cirrhosis would be foolish were it not 
for some encouraging signs. Of 46 patients 
treated with conventional immunosuppres-
sion between 1963 and the end of 1979, 16 
lived for at least 1 year9 and 10 are still alive 
after 31/4 to 9 years. Whether survival of these 
high risk patients can be greatly improved 
by use of cyclosporine and steroids is under 
study. 
Risks to medical personnel have been sub-
stantial. All but one of the surgeons of the 
1963 Colorado liver team had one (and in 
one case, 2) bouts of acute hepatitis, and the 
chief research technician in that effort died 
of the disease. Within the last year, one of 
the surgical fellows in Pittsburgh has had B-
virus hepatitis. A program has been in place 
to protect personnel with isolation tech-
niques in and outside the operating room, to 
treat them with hyperimmune globulin after 
overt exposure, and to carry out active im-
munization of those who elect to participate 
in this potentially hazardous patient care 
program. 
The need has been acknowledged for pol-
icy changes in our decision to continue these 
efforts. We are now recommending operation 
at an earlier time and with as short an interval 
as possible between acceptance to candidacy 
and transplantation, particularly for recipi-
ents whose livers are demonstrated to be tiny 
by ultrasonography and computed tomogra-
phy. The liver size, as estimated by these 
imaging procedures, has been within 10% of 
the actual volumes of the eventually excised 
livers. 
As new hepatic transplantation centers are 
established, their responsibility will be to 
treat patients from their regions who have 
underlying chronic aggressive hepatitis. 
However, prudence may dictate that trials at 
a new center begin with the less difficult 
diseases summarized in Table 176-3. Other-
wise, the indelible image may be left with 
the participants and onlookers that liver 
transplantation is a murderously difficult and 
hopelessly complex enterprise that exceeds 
the capabilities of the sponsoring institution. 
Biliary Atresia. Sixty-two patients have 
been treated to date. The prevalence of biliary 
atresia in Europe and the United States has 
been estimated as between 1 in 7000 and 1 
in 13,000 births (Chapter 178). With approx-
imately 3.7 million births each year in the 
United States,57 the annual number of new 
patients with biliary atresia should be ap-
proximately 400 to 500. Not all would be bona 
fide candidates for liver transplantation, since 
severe associated anomalies of other organ 
systems have been estimated to occur in 
about 15% of these children. 
Several patients with biliary atresia have 
died after liver transplantation because of 
unexpected intra-abdominal anomalies that 
jeopardized performance of a technically sat-
isfactory transplantation. 13•29 The most seri-
ous variations have included an absent infe-
rior vena cava, a pre-duodenal portal vein, a 
hypoplastic portal vein, and an hepatic arte-
rial blood supply that was unsuitable for 
arterial reconstruction. Three patients had a 
complex of anomalies that included intestinal 
malrotation, a pre-duodenal portal vein, an 
absent retrohepatic inferior vena cava, and a 
small hepatic artery that originated from the 
superior mesenteric artery.13.58 One of these 
recipients had a successful transplantation 
and is still living 8V2 years postoperatively. 
The propriety question has never been an 
issue in deciding upon transplantation (Table 
176-3), and the question of feasibility has 
been clarified by experience. Since 1975, most 
of the infants and children who have come 
to transplantation have had a previous at-
tempt at porticoenterostomy (Kasai proce-
dure) with the construction of a Roux-limb 
of jejunum. Partly because of cholangitis, 
common after porticoenterostomy, an in-
creasing number of patients with biliary atre-
sia have had multiple operations, including 
diverting skin jejunostomies. These, in turn, 
have often required later closure because of 
bleeding or ulceration. The consequence has 
been that the ultimate step of liver replace-
ment has become increasingly difficult. Un-
der such circumstances, extensive and highly 
vascular adhesions are almost always present 
in the hilar area and frequently around the 
entire liver surface as well. 
Despite these technical disadvantages, the 
care of children with biliary atresia can be a 
rewarding experience. The interval between 
the realization that a porticoenterostomy has 
failed and death usually is many months. 
Thus, the transplantation can be planned in 
a relatively elective fashion and carried out 
before profound clotting abnormalities and 
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other severe metabolic perturbations de-
velop. 
When hepatic transplantation was carried 
out under conventional immunosuppression, 
the I-year survival of patients with biliary 
atresia was only 27%;29 most of the deaths 
occurred in the first 3 months. The situation 
has drastically changed since the introduc-
tion of cyclosporine and steroids; the major-
ity of patients treated since then are living 
with excellent or completely normal liver 
function with follow-ups of as long as 3 
years. 29 
Hepatic Malignancy. When clinical liver 
transplantation was first performed, a pri-
mary malignant neoplasm of the liver that 
could not be removed by a conventional 
operation was thought to be an ideal indica-
tion for liver replacement. The outcome with-
out excisional therapy was highly predict-
able. The patients were in generally good 
condition and did not deteriorate rapidly 
while waiting. Hepatic function, including 
coagulation, usually was not gravely de-
ranged. Because portal hypertension seldom 
was severe and because the native livers were 
of normal size or enlarged, the technical 
demands of the transplantation were rela-
tively simple in comparison with the stand-
ards required in cirrhotic recipients. How-
ever, the great frequency of subsequent 
metastases after total hepatectomy and trans-
plantation, yP~vKRgKR9SM as well as the recognition 
that immunosuppression could theoretically 
accelerate metastatic growth, 13 quickly damp-
ened enthusiasm for this procedure. The con-
sequence has been that decisions about can-
didacv are more controversial than ever 
(Table 176-3). 
At the same time as the specter of meta-
static disease was emerging, n other evidence 
was developing that recurrence was not in-
evitable. One of CaIne's patients who died 
of biliary tract complications 5 years after 
transplantation for primary carcinoma had 
no detectable disease at necropsy.31.61 Two of 
the children we operated on, one with biliary 
atresia and the other with alpha-I-antitrypsin 
deficiency, had unsuspected incidental car-
cinomas in their excised livers and are well 
after 5 and 13V4 years respectively. 
PRECYCLOSPORINE ERA. From 1963 to the 
end of 1979, we performed liver transplan-
tation in 20 patients for the purpose of re-
moving a known primary malignancy. Eight 
of the recipients died in less than a month 
and only one had metastases at necropsy; 
thus, the preoperative screening for extra-
hepatic tumor spread had been relatively 
accurate. Of the other 12 who lived long 
enough for occult residual tumor to grow, 10 
(83%) developed metastases. Recurrent dis-
ease was the main cause of death in 5 survi-
vors who eventually died after 11, 13, 14, 24, 
and 54 months; the other 5 died primarily 
from other complications. The early and late 
metastases were from primary hepatocellular 
carcinoma, duct cell carcinomas, and one 
hemangioendotheliosarcoma. 29,59 One patient 
with an unclassified sarcoma is still well after 
more than 6 years. During this same period, 
CaIne et al. 56,60,61 reported a 50% to 65% 
frequency of metastases, which were partic-
ularly common and aggressive from primary 
duct cell tumors; the frequency of recurrence 
may have been misleadingly low, since 
deaths occurred so early that metastases that 
might have been inapparent even at necropsy 
were not stratified out of the computations. 
CYCLOSPORINE ERA. Later results with can-
cer patients have been less bleak. Between 
March 1980 and April 1982, 8 more patients 
had transplantation for known primary car-
cinomas. Three of the neoplasms were mas-
sive and were in livers that had no other 
disease; 2 were associated with chronic ag-
gressive hepatitis; and one each was associ-
ated with the cirrhosis of alpha-I-antitrypsin 
disease, tyrosinemia, and sea-blue histiocyte 
syndrome. The other 3 patients had duct cell 
carcinomas. All 11 recipients had immuno-
suppression with cyclosporine and steroids. 
Seven of the 8 patients with primary carci-
noma recovered fully from the operation. 
One died of recurrence 23/4 years later (dis-
cussed later). None of the other 6 has devel-
oped metastases after follow-ups of 11, 12, 
13, 17, 19, and 20 months. 
Unwarranted conclusions should not be 
drawn from these results. Special pathologic 
features could have conspired for success; 
the primary carcinomas that were associated 
with other diseases were localized enough so 
that they might have been removed by sub-
total hepatic resection were it not for the 
coexisting cirrhosis. The 3 massive tumors in 
otherwise normal livers were "fibrolamellar" 
carcinomas, neoplasms that are characterized 
by indolent primary growth and late metas-
tases. 62.63 Although draconian measures were 
required for their removal, recurrences have 
developed from only one of these tumors. In 
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this recipient (mentioned earlier), who died 
of carcinomatosis 2% years after liver replace-
ment, a large tumor thrombus originating in 
a hepatic vein was extracted from the vena 
cava and right atrium at the time of trans-
plantation. A second patient operated upon 
13/4 years ago had complete obstruction of 
the portal vein by tumor but has had no 
recurrence. A third patient developed recur-
rences in the residual lateral segment after a 
right trisegmentectomy performed 4V2 years 
earlier. The tumor-laden hepatic remnant 
and left diaphragm were removed in the 
course of an I8-hour transplant operation, 
and she has been well for 11 months. 
The results in 3 patients who were treated 
for duct cell carcinomas during the same 
period and under the same immunosuppres-
sion provide a stark contrast. One of the 3 
died early of surgical complications. The 
other 2 had a good convalescence but died 
of widespread metastases in the 9th and 13th 
postoperative months. To our knowledge, no 
patient has ever been cured of duct cell 
carcinoma by liver transplantation. 
More patients with primary hepatic malig-
nancy will be treated with transplantation, 
but the numbers will be kept small by in-
creasingly scrupulous case selection. 
Inborn Errors of Metabolism 
ALPHA-I-ANTITRYPSIN DEFICIENCY. This in-
born error of metabolism was seen in our 
series in 4 adults and 13 children (Tables 176-
1 and 176-2). The issues of case selection and 
surgical technique were the same as in those 
with chronic aggressive hepatitis. In fact, 
several of the patients carried the latter di-
agnosis until examination (or re-examination 
at a later time) of the surgical specimen. The 
difference is that the hepatic disease does 
not recur and the pulmonary complications 
of the disorder are probably aborted as well. 
After successful operation, the Pi (protease 
inhibitor) type converts to that of the donor 
and depressed serum alpha-I-antitrypsin lev-
els become normal. 29.64.65 The longest survival 
of a patient with this diagnosis has been 
more than 6V2 years. 
OTHER INBORN ERRORS. Five other diseases 
have been treated in 8 patients (Table 176-
1). Decisions about proceeding were easy 
because of the extent of hepatic failure or 
because the liver contained a neoplasm (Ta-
ble 176-3). Although cirrhosis was present, 
the operations were technically easy. even in 
a patient with type I glycogen storage disease 
(GSD) who had undergone an end-to-side 
portacaval shunt 8 years previously. 
Metabolic "cure" of the original metabolic 
disease has been proved or presumed in all 
of the recipients except a child with type IV 
GSD who died too soon to permit the appro-
priate studies. Although the enzyme defect 
of Wilson's disease (if an enzyme deficiency is 
the etiology) is not known, the 3 boys with 
this disorder underwent total body decop-
pering.66-<>8 One died after 6 years of biliary 
tract complications. The other 2, who are 
well after 11/2 and 12 years, had complete 
reversal of severe pre-existing neurolOgic dis-
ability. A liver biopsy after several years in 
the longest survivor revealed a normal cop-
per concentration. 67 
Stabilization of severe neurologic disease 
has also been seen during 13 months after 
transplantation in a child with the sea-blue 
histiocyte syndrome (in spite of the fact that 
the explanation for this lipid storage disease 
is unknown68). However, a follow-up liver 
biopsy showed some deposition of lipid gran-
ules in the new liver, which may signal 
recurrence. Daloze et al. 3S have demons tra ted 
restoration of depressed sphingomyelinase 
for more than a year in a child with Niemann-
Pick lipid storage disease, but the patient's pre-
existing neurologic damage was too great and 
irreversible to permit survival:'. The hepatic 
enzyme defects in cOllgenital tyrosinemia (ty-
rosinase) and type I glycogen storage disease 
(glucose-6-phosphatase) are known. All of 
the characteristic metabolic perturbations of 
these disorders are rectified within a few 
hours after transplantation. 29.6S-70 
Now that the feasibility of such "metabolic 
engineering" has been established, the indi-
cations for this approach should proliferate 
and transplantation be carried out earlier. 
Alcoholic Cirrhosis. A decision to perform 
transplantation for alcoholic cirrhosis should 
be made free of illusions about the surgical 
difficulties that can be expected. Replacement 
of the rock hard and frequently small liver 
presents problems that are similar to or even 
worse than those already described for non-
alcoholic cirrhosis. A depressing number of 
candidates already have had a portal-sys-
temic diversion or some other intra-abdomi-
nal procedure to control variceal hemor-
rhage. 
The screening of candidates for such a 
herculean effort is by no means easy (Table 
176-3) 
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176-3). A surprising number of patients sent 
to us with the diagnosis of alcoholic hepatitis 
have had some other disease. A bona ~de 
candidate with non-alcoholic hepatic disease 
who is beyond help by conventional therapy 
might be someone whose physical condition 
is relentlessly deteriorating; who has pro-
gressive jaundice, hypoproteinemia, pro-
thrombin depression, and other worsening 
indices of liver function; and whose mental 
competence is failing. Even if the liver is 
shrunken, how much survival time remains, 
and how urgent is the need to find a donor 
are difficult to estimate. Finally, since many 
alcoholic patients follow other avenues of 
self-abuse, disease of the lungs and other 
organ systems is common. 
If transplantation is successful, non-com-
pliance and recidivism may be a problem. Of 
the first 9 alcoholics in our series, 8 died too 
soon to evaluate this potential problem. ~1 
Three of the next 6 had prolonged survival. 
Of the 4 who lived for at least a year, 3 are 
still alive and "dry" with follow-ups of 5V2, 
6, and 9 years. The late death was after 55 
months in a young man who resumed drink-
ing and IV drug abuse and developed fatal 
pneumonitis. Of the 15 alcoholics listed in 
Table 176-2, none have been treated in the 
last 3 years. 
Despite these characteristics, alcoholic cir-
rhosis probably will become a more frequent 
indication for transplantation. If so, the up-
per age limit probably should be lowered 
from 55 years and a significant period of 
alcohol abstinence should be mandatorv. The 
latter step alone will cull the candidacy list, 
either by making the patient too well to be 
considered further or by proving the infeas-
ibility of reform. Those who adhere to a 
rehabilitation program without improving 
should be offered transplantation much ear-
lier than has ever been done in the past. 
Primary Biliary Cirrhosis (PBC). Because 
the natural history of this disease has been 
so well documentedn.73 and is so predictable, 
transplantation can be used before an agonal 
phase is reached. If the serum bilirubin con-
centration begins a steady rise and exceeds 
10 mg/dl average survival is limited to about 
18 months. 72 .73 Further ways are available to 
identify those patients who cannot meet or 
can be expected to exceed this average. 72 The 
final events of the disease move slowly 
enough that there is reasonable time (some-
times many months) to search for a donor 
after selection as a candidate. 
Transplantation for PBC is easier than for 
any other disease (Table 176-3). The liver is 
of °normal size or enlarged, the venous col-
laterals are not excessive, and occlusion of 
the recipient portal vein and vena cava dur-
ing the anhepatic phase is well tolerated. 
Recurrence of PBC after transplantation has 
been described. 7' However, we have not seen 
this complication in recipients followed for 
as long as 4213 years despite the invariable 
reappearance of mitochondrial antibodies. 75 
Sclerosing Cholangitis. Because the final 
stages of this disease have not been as well 
studied as those in PBC, decisions for trans-
plantation have come late. Another adverse 
factor has been the frequency of previous 
biliary tract procedures, including choledoch-
oenterostomies (Table 176-3). Transplanta-
tion in such patients may be technically im-
possible if not decided upon before the 
development of serious metabolic perturba-
tions. 
As more liver transplantation centers are 
opened and liver transplantation is recog-
nized as an option at the end of the line, the 
attitudes of gastroenterologists and surgeons 
may become more conservative about mini-
mally effective palliative operations such as 
choledochoenterostomy, which may make 
definitive treatment with transplantation 
impossible. Further impetus toward non-
operative management has already been 
provided by the ability to achieve biliary 
decompression by non-surgical means 
(Chapters 195 and 196). 
Whether recurrence of the cholangitis will 
be a problem is not known. However, the 
overwhelming prevalence of associated and 
presumably causal disease in the intestinal 
tract (especially ulcerative colitis) and else-
where portends an added risk. If quiescent 
ulcerative colitis is present, the question of 
colectomy to prevent recurrence of the liver 
disease in the transplant will be a consider-
ation, but no experience indicates if or when 
this should be done. Our present opinion is 
that colectomy should be put off until after 
transplantation to avoid the intra-abdominal 
adhesions and possible ileostomy that would 
jeopardize liver replacement. Only 4 of the 
10 recipients with sclerosing cholangitis in 
our series have had long survivals. Two of 
them died after more than a year with no 
evidence of recurrent disease in the homo-
grafts at necropsy. 
Secondary Biliary Cirrhosis. The initiating 
event in each of our 9 cases of chronic biliary 
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obstruction (see footnotes in Tables 176-1 
and 176-2) precipitated a series of attempts 
at biliary reconstruction. If such patients are 
accepted as transplant candidates, the tech-
nical risks must be recognized as enormous 
(Table 176-3). Four of the 9 recipients died 
during or just after operation. Yet, disease 
does not recur if the procedure is successful. 
Budd-Chiari Syndrome. The possibility that 
portal-systemic diversion can help these pa-
tients may lead to a decision for such an 
attempt and could thereby preclude subse-
quent transplantation. However, 2 of our 4 
patients had undergone side-to-side porta-
caval shunts that were successfully taken 
down at the time of transplantation. Recur-
rent lethal Budd-Chiari syndrome has been 
described bv CaIne et al. 56 and in one of our 
patients who died after 15 months. 76 In both 
cases, anticoagulation had recently been dis-
continued. A second of our 4 recipients died 
after 20 months, a few days after retransplan-
tation for chronic rejection. The other 2 are 
alive after 2314 and 8V2 years; the longest 
survivor has had 2 children. 
Miscellaneous Indications (Tables 176-1 to 
176-3). Finding an organ for patients with 
acute disease after no hope other than trans-
plantation remains for survival is rare. The 
patient with acute hepatitis in our series was 
the only example of a recipient with acute 
hepatic failure in our first 237 cases of ortho-
topic transplantation. 29 Other patients were 
considered but developed evidence of brain 
stem herniation and died within a few hours 
after admission. 
Tissue Matching. Waiting for good 
matches at the A, B, and DR loci is not 
practical and probably never will be because 
of the precarious condition of the recipients. 
Usually time is not sufficient to determine 
the presence in the recipient serum of the T-
warm antidonor antibodies that cause hyper-
acute rejection of kidney homografts. Hepatic 
transplantation often has been performed by 
US29.5Iil77 and by the Cambridge-King's Col-
lege team78.79 despite positive cytotoxic cross-
matches. To our knowledge, hyperacute re-
jection of the liver has never been seen. 
Much more experience is required before 
concluding that acceptance of positive cross-
matches caused by T-warm recipient antibod-
ies is without jeopardy. Patients for whom 
cross-matches could not be performed or 
whose sera crossmatched negatively with do-
nor lymphocytes had better results than 
those who cross matched positively.29 Al-
though hyperacute rejection was not ob-
served in the latter recipients, the postoper-
ative courses tended to be stormy, and at 
least 2 of the livers developed delayed mas-
sive necrosis. 
The liver is resistant to hyperacute rejec-
tion. However, in animal xenograft models 
in which the recipient has pre-formed hetero-
specific cytotoxins, humoral antibody rejec-
tion of the liver is merely slower than that of 
the kidneyso; the mechanisms of destruction 
are the same. The extent (if any) to which 
the outcome after clinical liver transplanta-
tion is degraded by pre-formed antibodies 
will be important to observe. Many liver 
transplant candidates have widely reacting 
T -warm cytotoxic antibodies reflecting sensi-
tization by previous blood transfusions. 
These make it difficult to find a cross-match-
negative donor but we continue to treat such 
highly sensitized patients. 
If donor-recipient ABO blood group incom-
patibility exists, renal grafts can be destroyed 
by isoagglutinins. 81 Liver grafts, however, are 
resistant to this kind of hyperacute rejec-
tion.71 ABO-incompatible donors were used 
in only 2 of our Pittsburgh patients. 29 One of 
these patients had a good recovery and now 
is alive 2 years postoperatively; the other 
died of aspergillosis. We have tried to avoid 
violating blood group barriers, since group-
compatible donors usually can be found. 
The Donor Operation. Removal of a satis-
factory liver for transplantation begins with 
wise screening of donors and elimination of 
those whose physiologic situation could jeop-
ardize vital organ function in advance of 
procurement. Aside from abnormalities in 
hepatic function, signals that it may be dan-
gerous to transplant the liver of a given donor 
to a recipient are donor cardiovascular insta-
bility, a need for excessive vasopressor sup-
port, an excessive period (several days) be-
tween injury and the pronouncement of 
brain death, or deterioration of renal func-
tion, which may suggest poor perfusion of 
other organs. 13,82 The most common expla-
nation for transplantation of an inadequately 
preserved liver is pre-existing hepatic injury, 
rather than poor harvesting or preservation 
techniques. 
Assuming that donor selection has been 
appropriate, removal of an adequate liver 
depends upon: (1) performing a good oper-
ation, including recognition and protection 
F 
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from injury of anomalies of the hepatic arte-
rial supply (Fig. 176-4); (2) avoiding hepatic 
warm ischemia; and (3) minimizing hepatic 
cold ischemia. The first of these provisos is 
dependent on the knowledge and skill of the 
donor surgeon. The second can be met by 
avoiding occlusion of the blood supply dur-
ing dissection and by efficient infusion of 
cold solutions into the liver as the donor 
operation is terminated. The third requires 
careful timing of the donor and recipient 
operations, which often take place across 
great geographic distances. When the new 
liver arrives at the operating room of the 
recipient, the team there should be ready 
within a few minutes to begin its insertion. 
With the preservation techniques available 
today,85,86 an ischemic interval greater than 6 
or 8 hours is not safe. 
Contingency Vascular Grafts. After the or-
gans are out, the distal aorta and vena cava, 
the iliac veins, and the iliac arteries are re-
moved and stored separately in balanced 
electrolyte solution.87 Often these vascular 
segments have been desperately needed for 
the subsequent performance of a renal or 
hepatic transplantation (Fig. 176-5). 
The Recipient Operation. A bilateral sub-
costal incision is used with an upper midline 
extension through which the xiphoid process 
is excised (Fig. 176--6). The midline extension 
with xiphoid removal provides badly needed 
A. 
anomalous left hepatIC A 
common hepatIC A. 
gastroduodenal 
A. 
anomalous rl. 
hepatic A. 
Figure 176-4. Anomalies of hepatic supply. (From 
Shaw BW Jr et ai. Surg Gynecol Obstet 1982; 
155:.321-5. Reproduced with permission.) 
exposure for dissection of the hepatic liga-
ments and the suprahepatic inferior vena 
cava. If removal of the liver will be a struggle, 
another extension should be made immedi-
ately into the right seventh intercostal space 
(Fig. 176--6). This is most commonly needed 
if the liver is unusually shrunken. In such 
cases, special techniques may be needed to 
construct vena caval cuffs for later anasto-
moses. 88,89 
M~--
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lEo I fnfe~Ior I 
vena caval,' 
graft ' 
Portal vein 
graft 
I 
\ 
\ 
Arterlograft to 
Infrarenal aorta 
figure 176-5. The uses to which aortic. vena cavaL and iliac vascular grafts have been put in renal (A) and 
hepatic (8) transplantation. (From Starzl TE et al. Surg Gynecol Obstet 1979; 149:737. Reproduced with 
permission. ) 
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Figure 176-6. Incisions for orthotopic liver transplan· 
tations and for hepatic resections. right or left. Note 
that several extensions may be made from the basic 
right subcostal incision. A to A. that is almost always 
used. More than one of the depicted extensions may 
be required in a given patient. (From Starzl TE et al. 
Surg Gynecol Obstet 1975: 141:429-37. Reproduced 
with permission.) 
With the liver out, the wound is checked 
for major sites of bleeding, realizing that total 
hemostasis of the bare area and elsewhere is 
not possible at this time. The suprahepatic 
and infrahepatic vena caval anastomoses are 
performed first, followed usually by recon-
struction of the portal vein. At a convenient 
time, air and. the potassium-rich preservation 
fluid in the graft should be washed out (Fig. 
176--7) to prevent air embolism or hyperka-
lemia with revascularization. Portal blood 
flow is usually restored first. After checking 
for major anastomotic leaks, the hepatic ar-
terial anastomosis is performed. Special 
techniques91.92 have been developed for the 
various vascular anastomoses, which often 
must be performed intraluminally or in close 
quarters. 
Frequently, the new liver is at first swollen 
and hard, with diffuse hemorrhage from all 
raw areas. With time and the administration 
of platelets and fresh frozen plasma, the 
problems are usually reversible, provided a 
major bleeder has not been missed. Efforts 
at mechanical hemostasis are continued until 
it is thought safe to perform the biliary tract 
reconstruction. 
Venous Bypasses. Portal and vena caval 
occlusion usually is reasonably well tolerated 
during a 45- to 90-minute anhepatic phase 
despite major declines in cardiac output and 
variable hypotension. 93 The relative safety of 
the occlusions depends on the collaterals that 
develop with human liver disease. The same 
thing has been demonstrated in dogs sub-
jected to chronic bile duct obstruction. 94 Be-
cause of this, we abandoned the venous 
bypasses that we used in all of our first 
cases. 7•24 However, some patients can be 
gravely jeopardized by the venous cross-
clamping. If severe hypotension occurs after 
cross-clamping, Caine et a1. 56,95 have recom-
mended femoral vein to femoral artery by-
pass with an intervening oxygenator. About 
10% of the English patients are so treated. 
One death during the last year in our series 
could have been avoided by this precaution, 
as could a cardiac arrest that was successfully 
treated. 
The fact that most patients can recover 
from portal and inferior vena caval cross-
clamping may have created a false impres-
sion about the safety of this practice. Usually 
the intestine grossly swells during the period 
of portal occlusion. Subsequently, many pa-
tients suffer from third space fluid sequestra-
tion and from postoperative renal failure. The 
extent to which these complex physiologic 
events have contributed to the high periop-
erative mortality of liver transplantation has 
not been delineated. For this reason we have 
returned in some cases to the practice of 
venous bypass, which we abandoned long 
ago. Cannulas are placed into the inferior 
vena cava through an iliac or femoral vein 
and into the portal system through the open 
end of the transected portal vein. During the 
anhepatic phase the blood is returned to a 
reservoir and pumped to one of the large 
veins in the neck or arm. This bypass requires 
total body heparinization, and the amount of 
bleeding that is induced may be so excessive 
and unresponsive to protamine reversal as to 
result in death on the operating table. The 
possibility of using pump-driven venous by-
passes without heparin is being evaluated in 
dogs. The canine experience thus far has 
been encouraging. 
If venous bypass without heparin becomes 
feasible, liver transplantation will be possible 
with maintenance of better homeostasis and 
without as much stress on the anesthesiolo-
gists and surgeons. Removal of the devas-
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Low molecular wel9h1 
dex1. (COld. 
Suprahepatic anastomo"s 
Figure 176-7. Initial steps in the im· 
plantation of a new liver. A. Infusion 
with lactated Ringer's solution in order 
to wash out the potassium-rich Collins' 
solution. fj, Completion of suprahepatic 
anastomosis. C, Completion of infra-
hepatic vena cava anastomosis. fj and 
C, Note the escape of air bubbles that 
if not expelled, could lead to air embo-
lism. (From Starzl TE et a!. Ann Surg 
1978; 187:236-40. Reproduced with 
permission. ) 
A_ 
cularized liver in a meticulous and deliberate 
way, as well as more leisurely performance 
of the vascular anastomoses, could for the 
first time make transplantation a pleasant 
operation instead of a desperate race against 
the clock. 
Technical Problems and Solutions 
"FROZEN" LIVER HILUS. Patients with pre-
vious operations may have such severe right 
upper quadrant adhesions that it is virtually 
impossible to enter the abdomen. Developing 
an exact plane on the undersurface of the 
liver with sharp dissection is essential in such 
recipients to eventually encircle the porta 
hepatis. If the lesser omental sac can be 
found and entered through the avascular 
gastrohepatic ligament, the encirclement 
usuallv is easiest from the left side. If dis-
secting the individual structures of the porta 
hepatis is then impossible, the triad can be 
transected after the mass placement of a 
vascular clamp. The individual structures can 
be identified at the cut surface and traced 
back for the development of cuffs. 
ARTERlALIZA nON OF GRAFT ANOMALIES. 
Problems posed by homograft arterial anom-
alies (Fig. 176-4) have been described along 
with various technical solutions.13 A double 
4:;. 
arterial supply originating from the celiac axis 
and superior mesenteric artery once was 
thought to be too troublesome to warrant an 
effort at reconstruction. In several cases, the 
celiac axis and superior mesenteric artery 
have been connected (Fig. 17&-8), and one 
or the other end of the superior mesenteric 
artery has been anastomosed to the recipient 
hepatic artery. % 
INADEQUATE RECIPIENT ARTERY. Contin-
gency plans should be made in the event 
that a recipient hepatic artery is too small or 
too inconveniently located to permit an effec-
tive anastomosis. The most common cause is 
an anomalous recipient arterial supply. At-
tempts were made in our earliest experience 
in such recipients to perform an anastomosis 
of the graft aorta or celiac axis to the aorta of 
the recipient above the recipient celiac axis. 
The dissection required to clean off the recip-
ient aorta in this inaccessible area was diffi-
cult, and aortic cross-clamping, which was 
usually required during the anastomosis, 
had devastating physiologic effects. Conse-
quently, this approach has been abandoned. 
The easiest solution is to attach the homo-
graft blood supply to the recipient abdominal 
aorta, inferior to the origin of the renal arter-
ies (Fig. 17&-9). The extra length of graft 
I 
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Figure 176-8. The management of a common graft anomaly in which part of the hepatic blood supply is 
derived from the superior mesenteric artery. Note that the celiac axis is anastomosed to one end of the main 
superior mesenteric artery and the other end is used for anastomosis to a recipient vessel. (From Shaw BW Jr 
et al. Surg Gynecol Obstel in press. Reproduced with permission.) 
vessel necessary to reach this location can be 
provided by retaining the thoracic aorta of 
the donor in continuity with the celiac axis 
and by turning the aorta 1800 (Fig. 176-9). 
The occasional need for this technical devia-
tion has prompted the donor team to retain 
the thoracic aorta with the specimen when-
ever possible. 
Another option to obtain the needed 
length% is to anastomose the free common 
iliac artery graft to the same location in the 
reCipient aorta with ligation of the hypogas-
tric artery (Fig. 176-9). The external iliac 
artery is almost a perfect match for anasto-
mosis to the graft celiac axis (Fig. 176-9). 
THROMBOSED OR HYPOPLASTIC PORTAL VEIN. 
One of the great tragedies of liver transplan-
tation has been the discovery at operation of 
an unsuspected thrombosis or hypoplasia of 
the portal vein. If effective revascularization 
of the homograft portal vein has not been 
accomplished, survival has never been ob-
tained. In 2 patients, the suprarenal inferior 
vena cava was anastomosed to the graft por-
tal vein, providing the live; with systemic 
venous inflow, as with a portacaval trans-
position. This anastomosis thrombosed in 
one patient, who died of massive hemor-
rhage from esophageal varices a month later; 
the other patient died of massive graft necro-
sis. 
If the thrombosis (or hypoplasia) has not 
involved the splenic and superior mesenteric 
veins, the confluence of these portal tributar-
ies can be dissected free from beneath the 
pancreas. We have then developed a cloaca 
at this junction to which an iliac vein graft 
has been anastomosed to provide added 
length. The use of an interposition host graft 
under these circumstances (Fig. 176-5) has 
been life saving. If thrombosis of the portal 
vein has been recent, thrombophlebectomy 
has been accomplished on several occasions. 
Although a rough intimal surface has been 
left, the portal venous system has remained 
open. 
BILIARY TRACT RECONSTRCCTION. The most 
common technical complications in the early 
days of liver transplantation originated from 
defects in biliary tract reconstruction. 3197.98 
These were often not recognized and led to 
the death of many patients. Because of its 
convenience, the now abandoned procedure 
of cholecystoduodenostomy was frequently 
used (Fig. 176-10E). Obstruction at the 
homograft cystic duct occurred in almost half 
the cases. Even without obstruction, the bil-
iary tract became the site of entry of bacteria. 
The frequency of bacteremia was astonish-
ing, sometimes occurring in asymptomatic 
patients. The organisms recoverable from the 
bloodstream were those indigenous to the 
gastrointestinal tract.13 We envisioned that 
the liver was being frequently contaminated 
with enteric contents, followed by systemic 
dissemination of the bacteria. 
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figure 176-9. Technical solution if an adequate recip-
ient artery cannot be found in the area of the portal 
triad. A piece of graft aorta in continuity with the graft 
celiac axis can be anastomosed to the abdominal aorta 
of the recipient. Alternatively. an iliac artery graft can 
be attached to the recipient aorta with a distal anas· 
tomosis to the celiac axis. The latter technique de-
pends upon the availability of contingency grafts pro-
cured at the time of liver harvest (Fig. 176-5). (From 
Shaw BW Jr et aJ. Surg Gynecol Obstet. in press . 
Reproduced with permission.) 
The results were improvea with the sys-
tematic use of a defunctionalized jejunal limb 
(Roux-en-Y) to which the gallbladder was 
anastomosed (Fig. 176-10F). However, the 
problem of cystic duct obstruction in more 
than one-third of the recipients remained 
(Fig. 176-11), necessitating frequent secon-
dary revisions with conversion to choledo-
chojejunostomy (Fig. 176-10B). Our present 
practice if biliary-enteric anastomosis is nec-
essary (as is invariably the case with biliary 
atresia) is to perform a choledochojejunos-
tomy (Roux-en-Y) at the first operation (Fig. 
176-10B). This is done with a single layer of 
continuous absorbable suture; a few tacking 
sutures can be used for reinforcement and 
an internal stent is used. When choledocho-
jejunostomy is performed, the gallbladder is 
removed. 
Biliary tract reconstruction by duct-to-duct 
anastomosis was used by us at first and then 
was temporarily abandoned because of a 
large number of biliary leaks, which were 
lethal in the patients treated 15 to 20 years 
ago. The duct-to-duct anastomosis is per-
formed with interrupted absorbable sutures 
(Fig. 176-10A). AT-tube stent is used when-
ever possible, and the T-limb is brought out 
through a choledochotomy in the recipient 
portion of the composite duct. In small chil-
dren, and occasionally in adults, the available 
T-tubes are too small and an internal stent is 
used with the distal tip passed into the duo-
denum. The homograft common duct must 
figure 176-10. Methods of biliary tract reconstruction 
that have been used with liver transplantation. The 
techniques shown in E and F are so defective that they 
have been abandoned. Depending upon the anatomic 
and clinical circumstances. each of the other methods 
may be useful in individual cases (see text for discus-
sion). 
l 
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Figure 176-11. Transhepatic cholangiograms in 4 patients whose original biliary reconstructions were with 
Roux-en-Y cholecystojejunostomy. A Minimal obstruction. fl, Moderate obstruction. C, Severe obstruction with 
leak and abscess formation. D, Very severe obstruction; at reoperation the common duct was necrotic. A = 
leak and abscess formation; C = common duct; CD = cystic duct; GB = gallbladder; J = jejunum; large arrow 
= site of common duct ligation. (From Starzl TE et al. Surgery 1977; 81 :212-21. Reproduced with permission.) 
be cut high enough that its tip is well arte-
rialized. Studies have shown that the blood 
supply of the graft is dependent upon retro-
grade perfusion from hilar vessels. 99 
Waddell and Grover lOO recommended that 
the homograft duct be anastomosed to the 
graft gallbladder as part of the biliary recon-
struction in liver transplantation. CaIne has 
used this technique extensively, and for him 
it is the method of choice. 79. 101 The distal 
anastomosis with the fundus of the homo-
graft gallbladder is made either to the recip-
ient common bile duct (Fig. 176-10C) or to a 
Roux-limb of jejunum (Fig. 176-100). In 
either case, both of the anastomoses are 
stented with a T-tube, which can be used for 
irrigation. We have used the Waddell-Caine 
procedure only when the extra length pro-
vided by the gallbladder was necessary to 
bridge a gap between the graft and the distal 
anastomosis. 
An assessment of the various forms of 
biliary tract reconstruction used by us in 78 
consecutive cases has been published by 
Iwatsuki et aL 102 Choledochocholedochos-
tomy and choledochojejunostomy have both 
provided excellent results. Our experience 
with the Waddell-Caine procedure has been 
too limited to warrant comment, but the 
Cambridge team has been pleased with the 
results. 56 
CONTROL OF HEMORRHAGE. The most im-
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portant mechanical basis for bleeding in pa-
tients undergoing liver transplantation is por-
tal hypertension with extensive venous 
collaterals. Coagulation defects must be an-
ticipated, with depletion of clotting factors 
produced by the liver constituting a baseline 
condition. The situation may be aggravated 
by fibrinolysis, which may begin shortly be-
fore the revascularization of the homograft 
and which can assume crisis proportions 
shortly afterwards. The series of events in 
coagulation after liver transplantation was 
worked out before 1979.13.24.103.104 Develop-
ments in the coagulation field since that time 
may make the assessment and control of 
coagulation easier in the future. For example, 
there may be a place for the controlled use 
of antifibrinolytic agents such as epsilon-
amino-caproic acid (EACA), a drug that was 
abandoned more than a decade ago because 
its use was associated with the frequent oc-
currence of secondary clotting of the graft 
blood supply. Intraoperative changes in clot-
ting need to be reassessed by modern tech-
nology with a view to therapeutic modifica-
tions. 
Control of bleeding must start with the 
mechanical means of ligation, suture ligation, 
and cautery. With the new liver in place, the 
portal system is decompressed through the 
new organ with elimination of one adverse 
mechanical factor, i.e., portal hypertension. 
If the liver functions well, the perturbations 
in clotting can be expected to be self-correct-
ing, but this may require hours. Meanwhile, 
platelets, fresh frozen plasma, and blood 
constituents may be used as a temporary 
expedient. Some patients have lost as much 
as 200 units of blood during surgery but have 
left the operating room dry. 
Postoperative Care. Because grave meta-
bolic abnormalities predate operation in most 
patients, the postoperative care has often 
been an exercise in resuscitation. The most 
common early difficulties have been with 
pulmonary insufficiency (requiring mechani-
cal ventilation for several months in some 
cases), renal failure (at the same time that 
massive fluid shifts are occurring), and per-
sistent clotting abnormalities. These prob-
lems are managed with conventional meth-
ods of intensive care with great emphasis on 
biochemical and hemodynamic monitoring. 
Recovery can be expected from encephalop-
athy and the hepatorenal syndrome. lOS 
The ability to survive this critical period 
depends on what has just transpired in the 
operating room. Patients who have received 
well-functioning livers can have an almost 
miraculous recovery, but defective perform-
ance by the graft at the outset may preclude 
recovery unless another organ can be quickly 
found for retransplantation. 
The list of later complications is a long 
onen and includes peritonitis with or without 
bowel perforation, pancreatitis, pulmonary 
embolus, extra-abdominal infections, and 
psychosis. Many of these may be directly or 
indirectly related to the concomitant immu-
nosuppressive therapy. With an initially 
well-functioning liver, the most important 
prognostic factor is the ability to control later 
rejection. 
Immunosuppression. All of the methods 
to prevent or reverse rejection of whole or-
gans have been developed with the simpler 
procedure of renal transplantation. These are 
summarized in Table 176-4, exclusive of the 
earlier trials with total body irradiation106 
which was never used for liv'er transplanta-
tion. 
Azathioprine-Prednisone. Because the first 
genuinely promising drug, azathioprine, was 
ineffective when given alone,I07 azathioprine 
and prednisone, which have additive or pos-
sibly synergistic effects,llJ!>-lll were given to-
gether. 81 For organ transplantation, this has 
been the most commonlv used immuno-
suppression throughout the world for almost 
20 years. Our first 5 liver recipients and 
occasional later ones were treated with these 
drugs. The same treatment was used for 
almost all of the patients in the Cambridge 
series from 1968 until 1979. 
Under double drug treatment, irreversible 
rejection of cadaveric kidneys or their loss 
for other reasons during the first postopera-
tive year has been about 50%, even in later 
multicenter compilations. m.ll3 Double drug 
therapy is even less optimal in liver recipi-
ents, for whom cadaveric donors are obliga-
tory and who do not have the option of fall-
back maintenance on an artificial organ ther-
apy analogous to renal dialysis. 
Triple Drug Therapy. Alternative therapeu-
tic programs introduced for renal transplan-
tation between 1963 and 1979 (Table 176-4) 
were all modifications of or additions to the 
original double drug therapy. The most use-
ful was lymphoid depletion with antilympho-
cyte globulin (ALG),17 which was given 1M 
or IV as an adjunct to azathioprine and pred-
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in the past. With cyclosporine and steroids, 
kidney survival of greater than 80% can be 
expected 1 year after primary cadaveric trans-
plantation. 13 l. I32 
Nephrotoxicity is the most serious side 
effect of cyclosporine. 128-137 Fortunately, the 
renal complications are promptly reversed 
with the reduction of the cyclosporine doses. 
Most of the other side effects of cyclo-
sporine128-132 have not been serious; among 
them are gum hyperplasia, tremor, regional 
flushing or vague abdominal discomfort just 
after drug ingestion, and the development of 
breast fibroadenomas in women. Although 
hepatotoxicity has been seen in about one-
fifth of cases,138 this has rarely been serious 
and can be controlled by dose reduction. 
The most publicized question about cyclo-
sporine has concerned its role in causing 
lymphomas. 129 Lymphoma development 
with use of cyclosporine and steroids is not 
much (if at all) greater than with conventional 
immunosuppression. The evidence is that 
these lymphomas result from infections with 
the Epstein-Barr virus.l3I·m The risk of de 
novo epithelial malignancies may be less than 
with conventional immunosuppression, and, 
in fact, no such tumors have been reported, 
a striking but preliminary observation. Under 
conventional immunosuppression, epithelial 
tumors account for about 75% of the "new" 
malignant tumors. 139 
Cyclosporine and steroids for liver trans-
8 
I z OJ 
plantation have been adapted from the prac-
tices that first were standardized for kidney 
grafting. 14()...142 Cyclosporine is started a few 
hours preoperatively with an oral dose of 
17.5 mg/kg (Figs. 176-12 to 176-14). Cyclo-
sporine is continued daily, but with reduced 
1M doses (Figs. 176-12 and 176-13) or IV 
doses (Fig. 176-14) until diet is resumed. 
Subsequently, an oral dose of 17.5 mglkg/day 
is given, usually divided into twice daily 
doses. The doses are reduced subsequently 
if nephrotoxicity develops (Figs. 176-12 and 
176-13). Steroids also are started on the day 
of operation. For adult patients who leave 
the operating room in relatively good condi-
tion, a 5-day burst of prednisolone is given, 
starting at 200 mg and stopping with a main-
tenance dose of 20 mg/day (Fig. 176-12). 
Further reductions of cyclosporine and ste-
roid doses are made on an individualized 
basis in the ensuing months. Initial mainte-
nance therapy with steroids is scaled down 
in infants and children (Fig. 176-13). 
If the patient is in poor postoperative con-
dition, the initial burst of high dose steroid 
therapy is omitted for a few days or greatly 
reduced (Fig. 176-14). A few patients sus-
pected of having nephrotoxicity from cyclo-
sporine have been switched temporarily to 
azathioprine with resumption of cyclosporine 
treatment after improvement of renal func-
tion (Fig. 176-13). With less severe renal 
impairment (Fig. 176-12 and 176-14), the 
47 YEAR OLD l' 
44kQ 
figure 176-12. Double-drug im-
munosuppression with cyclospor-
ine and steroids. The patient had a 
hepatocellular carcinoma Ct,-anti-
trypsin deficiency, and chronic ac-
tive hepatitis. The reduction of the 
cyclosporine dosage after 4 days 
was because of the increaSing azo-
temia. The boluses of hydrocorti· 
sone were given because of a pos· 
sible unwarranted suspicion of 
early rejection. (From Starzl TE et 
al. Hepatology 1982; 2:614-36. 
Reproduced with pennission of the 
American Association for the Study 
of Liver Disease and Williams I!:t 
Wilkins.) 
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figure 176-L3. Immunosuppres-
sion with cyclosporine and steroids 
(plus temporary azathioprine) In a 
10-year-old girl. Note that the 5-
day opening burst of prednisone 
therapy was scaled down because 
of her smail size. The temporary 
discontinuance of cyclosporine and 
replacement with azathioprine be-
tween postoperative days 10 and 
15 was because of probable cyclo-
sporlne nephrotoxicity. The patient 
who was of B blood type. was given 
the liver of an A donor. (From Starzl 
TE et al. Hepatology 1982; 
2:614-36. Reproduced with per-
mission of the American Associa-
tion for the Study of Liver Disease 
and Williams l!t Wilkins.) 
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doses of cyclosporine can be reduced. Only 
one of our patients has been changed to 
azathioprine permanently. 
If rejection occurs in spite of this beginning 
therapy, the principal responses have been 
to administer intermittent large doses of hy-
drocortisone (or prednisolone) IV (Fig. 17£r 
12 and 17£r14), to repeat the original 5-day 
burst of steroids (Fig. 17£r14), or to settle at 
a higher maintenance level of steroids. Al-
though cyclosporine is not a drug that per-
mits much dose maneuverability, increasing 
the amounts given has sometimes been pos-
sible, the limiting factor being nephrotoxicity. 
Dose adjustments of cyclosporine can be 
aided by pharmacologic monitoring of 
plasma or blood levels. I43.1-14 
Most of the experience of CaIne et a1. 56 has 
been with delayed administration of this 
drug. Azathioprine (1.5 mglkg/day) and 
prednisolone (0.4 mg/kg/day) were used by 
them until renal and hepatic function were 
adequate. Then 10 mglkg/day of. cyclosporine 
was begun, and the steroid dose was slowly 
reduced to zero. The supervention of acute 
rejection during the interval of treatment 
with azathioprine and prednisone had been 
troublesome; CaIne et a1. 56 recommend short-
ening this period. 
Rejection Under Immunosuppression. 
Porter,I45 of London, studied the problem of 
hepatic rejection and immunosuppressive 
therapy in a variety of species, including 
man, and pieced together a clear picture in 
1969 that remains unchallenged today_ The 
concepts that came from his descriptions 
were developed with conventional immuno-
suppression, but in any given case they apply 
without revision when cyclosporine-steroid 
therapy is used. 
The first sign of rejection in untreated 
animals or in human recipients is the ap-
pearance in the liver of lymphoid cells (many 
with pyroninophilic cytoplasm) that leave the 
portal vein ramifications and probably the 
small arterial branches throughout the graft, 
accumulate in the portal tracts, and enter the 
central vein and the endothelial lining of the 
sinusoids. The cells invade the spaces of 
Disse, and some insinuate themselves be-
tween hepatocytes. With cellular infiltration, 
many of the sinusoids disintegrate, the blood 
flow through the liver begins to decrease, 12 
and some centrilobular cells die. Centrilobu-
lar necrosis progresses to mid-zonal necrosis, 
and liver function begins to deteriorate. At 
this late time (but not before), immunoglob-
ulins and complement can be found in the 
walls of small arteries, some of which de-
velop fibrinoid necrosis. 
Most of the foregoing studies were in dogs. 
When rejection is mild, as in pigs, 146 or when 
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Figure 176-14. Deviation from standard steroid therapy in a patient whose perioperative condition was frail. 
The 5-day burst of postoperative steroids was begun several days postoperatively but had to be repeated when 
rejection supervened. Before operation. the patient had the hepatorenal syndrome and encephalopathy and 
had been on a ventilator for more than 1 week. Because of defective clotting. efforts to place central venous 
lines before starting transplantation resulted in uncontrolled hemorrhage with loss of 20 liters of blood. The 
subclavian and innominate vessels were explored through cervical and thoracotomy incisions. and the bleeding 
was mechanically controlled before transplantation was started. The blood loss from placement of the vascular 
lines exceeded that incurred during transplantation. The patient survived because of prompt correction of the 
coagulation abnormalities. (From Starzl TE et al. Hepatology 1982; 2:614-36. Reproduced with permission of 
the American Association for the Study of Liver Disease and Williams &: Wilkins.) 
it is modified by treatment with immunosup-
pressive agents, as in dogs. rats, and 
man,I.;.147-149 the destruction of hepatocytes 
ceases, cellular infiltration diminishes and 
may disappear, and the central part of the 
lobular reticulin framework often collapses. 
Marked accumulation of bile in the surviving 
centrilobular hepatocytes and the bile cana-
liculi occurs, accounting for the hyperbiliru-
binemia that is characteristic of subacute and 
chronic rejection. A precise explanation of 
the cholestasis has not been established. 
Larger intralobular bile ducts become scarce 
in some patients as modified rejection be-
comes chronic. 78,7'/,145.150 
The progression from acute modified rejec-
tion to chronic rejection is not precise. Con-
necting bands of reticulin are often laid down 
between the central areas subdividing the 
lobules. On this framework, fibrosis may 
develop that can progress to true cirrhosis. 
Another characteristic feature of chronic re-
jection is intimal and subintimal thickening 
of the kind that has been seen in the arteries 
of renal and cardiac grafts. These vascular 
changes mayor may not be associated with 
the intramural deposition of immunoglobu-
lins and complement. 151 
The clinical manifestations of these patho-
logic changes have been varied, prompting 
attempts at classification by US lJ29 and by 
Williams and Calne. 31 The systemic manifes-
tations can include fever, malaise. anorexia, 
and depression. The grafts can become swol-
len and hard, and the patients may complain 
of right upper quadrant tenderness. Liver 
scans, whether involving parenchymal or re-
ticuloendothelial function, show poor uptake 
of the isotope. Poor synthetic function of the 
graft is detected most easily by measure-
ments of prothrombin time. Jaundice usually 
develops and may increase very slowly or 
with astonishing rapidity. Elevations in activ-
ity of the aminotransferases usually are seen 
.34 20 The Liver 
and, if these are extreme, prognosis is 
guarded. Occasionally, we have seen all of 
the manifestations of rejection but with min-
imal or no increases in serum bilirubin con-
centration; biopsies in these cases have 
shown marked cellular infiltration. This has 
been called "anicteric" rejection. 13 
The clinical syndrome just described, with 
any or all of its permutations, is non-specific. 
Hepatic injury, biliary obstruction, cholangi-
tis, hepatitis, and drug toxicity have been 
proved to be alternative explanations. For 
this reason, if the postoperative evolution 
has not been satisfactory, diagnostic proce-
dures such as cholangiography and needle 
biopsy must be promptly considered. Mean-
while, the steroid dosage is temporarily in-
creased with the understanding that it will 
be returned to baseline if a diagnosis other 
than rejection can be made. The possibility 
of an error in diagnosis is greatly increased 
and management made more difficult if good 
initial graft function is not achieved. 
Hepatic blood flow is drastically reduced 
with severe rejection,12 making the ischemic 
liver unusually susceptible to bacterial inva-
sion. Interaction has been shown in animaP52 
and in human13·153--155 studies between rejec-
tion and homograft bacterial colonization. 
Paradoxically, one of the important ways to 
prevent transhepatic infection of this kind is 
to protect the graft with potent immuno-
suppression, especially during the early post-
operative period. In addition, systematically 
designed antibiotic therapy should be given 
intraoperatively and for several days after-
wards. 
The clinical diagnosis of chronic rejection 
has been restricted to patients whose graft 
biopsies showed the arterial intimal thicken-
ing, hepatic fibrosis, and other findings al-
luded to before. The morphologic findings of 
chronic rejection have not been directly re-
lated to the postoperative interval, since they 
have been seen within the first few months. 
The clinical manifestations of chronic rejec-
tion have been similar to those with chronic 
liver failure from end-stage liver diseases of 
different causes. In contrast to acute rejec-
tion, chronic rejection cannot be effectively 
treated with increased immunosuppression. 
Survival After Liver Replacement. The in-
troduction of cyclosporine-steroid therapy 
has had a major influence on the results after 
orthotopic liver transplantation. 
The Precyclosporine Era. From 1963 to 
1979, 170 patients underwent orthotopic liver 
transplantation with conventional double 
drug or triple drug therapy. The I-year sur-
vival ranged between 28.8% and 50% 
throughout this time, but without an identi-
fiable trend of improvement. The results dur-
ing this 16-year period are summarized in 
Figure 176-15. 
Of the 170 patients in this series, 56 lived 
out the first postoperative year, 23 of whom 
subsequently died. 29 Although 13 of the 23 
late deaths were in the second postoperative 
year, losses occurred as late as 6 years. Of 
the original 170 patients, 33 (19.4%) are still 
alive after follow-ups of 3V2 to 131/3 years. 
Adult and pediatric recipients were almost 
equal (Tables 176-1 and 176-2). From the 
sixth month onward, the younger patients 
had about a 10% survival advantage. 
Occasional spectacular successes inter-
spersed with a larger number of failures were 
also the experience of the Cambridge-King's 
College trials from the beginning of that 
program in 1968 through early 1980.56. 60 In 
the English series, 22 (23.7%) of the first 93 
recipients lived for at least 1 year, with 11 
subsequent deaths during the second to sixth 
years; at the time of last reporting, the 11 
survivors had been followed for 1 to 6 years. 
The Cyclosporine Era. The predictability 
and reliability with which liver transplanta-
tion could be carried out improved abruptly 
with the first trials of cyclosporine-steroid 
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treated with cyclosporine and low·dose steroids com-
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conventional immunosuppression. The data for the 
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therapy/9,141l-142 and this improvement has 
been sustained. Since 1980, the majority of 
liver recipients have been able to leave the 
hospital for out-patient care. By May 1, 1982, 
40 recipients had been treated with this new 
immunosuppressive agent, with the survival 
projections shown in Figure 176-15. Since 
then, the survival of pediatric recipients has 
been maintained at about the same level, 
although less favorable results in adults have 
brought the I-year survival curve down. In 
addition, 3 of the patients treated with cy-
closporine and steroids who reached or 
passed the I-year mark died in their 13th, 
16th, and 20th postoperative months. The 
causes of the late deaths were recurrent car-
cinoma, recurrent Budd-Chiari syndrome, 
and chronic rejection (with unsuccessful re-
transplantation). 
The influence of cyclosporine upon sur-
vival in the Cambridge-King's College trials 
has not been clearly defined, in part because 
the drug has not been used regularly and in 
part because it had been started late in most 
cases after an initial course of azathioprine 
and steroids. Nevertheless, improved results 
have been attributed by CaIne et a1. 56 to the 
better immunosuppression which they can 
now provide with delayed cyclosporine. 
Causes of Mortality. The principal mortal-
ity after liver transplantation has been early 
in both the initial trials of liver transplanta-
tion under conventional immunosuppression 
and those with cyclosporine-steroid therapy. 
Detailed analyses of the causes for this 
mortality have been published. 13,29,51,54,88 
Throughout the years, the causes of failure 
have included the use of grafts damaged by 
ischemia, massive operative hemorrhage, 
thrombosis of the reconstituted homograft 
blood supply, intraoperative cerebral air em-
bolism, unsuspected recipient abnormalities 
(particularly of the porta hepatis structures), 
hopeless anatomic situations created by mul-
tiple previous operations, irreversible pre-
existing debilitation, and defective biliary 
tract reconstruction. Acute or subacute hom-
ograft rejection was also a factor, but its 
dimensions could not be clearly delineated. 
At necropsy, histopathologic findings of 
acute rejection have been found in a minority 
of cases. This prompted speculation in the 
earlier days, when biopsy was not often 
performed, that excessive immunosuppres-
sion, especially with prednisone, may have 
been responsible for unnecessary deaths. 
However, when serial biopsies were obtained 
in later cases,29,51,54 this view had to be re-
vised. Many of the biopsy specimens con-
tained unmistakable findings of rejection for 
which the appropriate response had been 
more steroids. Yet, after death, which was 
most commonly caused by terminal infection, 
findings of rejection were absent. This same 
chain of deadly events is still seen, but less 
frequently than before. 
Assessment of the reasons for late deaths, 
by contrast, has been less ambiguous. Recur-
rent liver failure was responsible for the 
deaths of three-quarters of the 26 patients 
who died after 1 year, if the 5 who died after 
attempted retransplantation are included. 29 
The dominant pathologic diagnoses in late 
failing grafts have been chronic rejection in 
the majority of cases, with biliary obstruc-
tion, recurrent carcinoma, chronic hepatitis, 
portal vein thrombosis, and recurrent Budd-
Chiari syndrome being progressively more 
distant contenders. 29 
These findings in long-term surviving pa-
tients are remarkably different from those 
reported by CaIne et a1. S6 in 11 patients who 
died after 1 year. Recurrent carcinoma was 
the main homograft abnormality in 5 of their 
patients. Biliary sludge and cholangitis were 
found in the other 6 grafts. Chronic rejection 
was not mentioned. Reconciliation of this 
divergence of observation will be important. 
Our findings suggest that ongoing problems 
with immunologic control will continue to 
take a gradual toll long after transplantation, 
whereas the interpretation of the pathologic 
findings in the English recipients diminishes 
the importance of chronic rejection, 
Steps to Reduce Mortality. A glance at the 
life survival curves from the earlier days of 
our experience, or even later (Fig. 176-15), 
shows that the highest priority for improved 
management is reduction of the perioperative 
mortality. However, the fact that the survival 
curves continue to decline even after 3 or 4 
months means that strategies to circumvent 
late mortality will also be important. Consid-
eration of policy adjustments that may have 
an impact in both periods is, therefore, of 
importance. 
Recipient Selection and Work-up. The way 
in which the original disease dictates the 
technical difficulty of transplantation (see 
earlier section on Indications) was not clearly 
perceived until relatively recently. The con-
sequent hidden risk factor could be improved 
! 
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by trying to treat patients with" dangerous" 
diseases (such as postnecrotic cirrhosis, al-
coholic cirrhosis, and secondary biliary cir-
rhosis) at an earlier time. When such patients 
have had previous operations at or near the 
hepatic hilum (such as repeated biliary tract 
reconstructions or, especially, portacaval 
shunts) liver transplantation is no longer a 
reasonable option in some cases, especially 
if the patient's physical and metabolic dete-
rioration is extreme. Almost all of our deaths 
on the operating table, and many not long 
afterwards, have been in such patients. 
The question of veno-venous bypasses 
during removal of the recipient liver and 
implantation of the new organ was discussed 
earlier. If candidates are accepted who have 
undergone a previous portacaval shunt, 
standby provisions should be made for the 
bypass, since the venous collaterals that usu-
ally make it safe to occlude the inferior vena 
cava and portal vein are apt to have under-
gone involution. Occasional other patients 
may be candidates for vena-venous by-
passes, but none with the predictability of 
the patient with previous portacaval shunt. 
Reservations were also expressed earlier 
about liver transplantation for postnecrotic 
cirrhosis in hepatitis B-virus carriers and pa-
tients with hepatic cancer. Evidence is insuf-
ficient to foreclose this avenue of treatment, 
but workers in the field must pool data to 
arrive at a consensus. Too many late deaths 
have occurred from recurrence of these dis-
eases. 
Incomplete knowledge of recipient anat-
omy cannot be accepted in future cases. Of 
all the adverse possibilities, an inadequate 
recipient portal vein is the most serious and 
the only one for which there usually is not a 
technical remedy. The means available to 
detect a defective portal vein must be em-
ployed to the fullest. 
Improvements in Criteria for Acceptable 
Donor Livers. Defective vascular or biliary 
tract anastomoses have become uncommon. 
The single most common problem is now the 
marginally functioning donor liver. When 
this has occurred, the orderly stages of donor 
liver removal have been found to be abridged 
or otherwise changed from the standard pro-
cedure. Another contributory factor has been 
acceptance of a physiologically unstable do-
nor who frequently has required large 
amounts of vasopressor medications for 
maintenance of blood pressure. The invest-
ment of so much time and effort by the 
physicians who obtained permlsslon to re-
move the liver or by the donor team (which 
frequently has flown to a distant city) may 
create a powerful compulsion to proceed in 
spite of warning signs. Abandonment of the 
donor effort under questionable circumstan-
ces will be increasingly necessary. 
Retransplantation. When a transplanted 
liver fails from rejection reaction or other 
causes, aggressive attempts at retransplan-
tation usually offer the only chance for sur-
vival. One of the most common judgment 
errors we have made is to hope vainly for 
improvement in hepatic function until the 
chance for reintervention is lost. Despite this, 
more than 30 patients have undergone re-
transplantation since 1968. 29 These efforts 
have become encouraging. More than a 
dozen patients treated in 1980 to 1982 had 
retransplantation a few days to 20 months 
after primary grafting and the majority are 
surviving with subsequent follow-up periods 
of up to 11/2 years. 
The performance of retransplantation has 
usually been surprisingly easy. The proce-
dure has been greatly simplified by retaining 
cuffs from the suprahepatic and infrahepatic 
vena cava and from the portal vein of the 
first graft. Usually, performing the arterial 
anastomosis proximal to the previous site of 
anastomosis has been necessary. 
Option of Auxiliary Liver Transplanta-
tion. Clinical efforts to transplant an extra 
liver (auxiliary transplantation) without re-
moval of the diseased native organ have been 
discouraging. l56 Of more than 50 well-docu-
mented auxiliary transplantations, only 2 
could be pronounced unequivocal suc-
cesses--one in New York City l56 and the 
other in Paris. 157 
Auxiliary liver transplantation may be use-
ful in patients with potentially reversible he-
patic disease. The extra liver could be used 
as a temporary support organ and later re-
moved. We are seeing more patients with 
chronic disease whose portal veins have clot-
ted in the hepatic hilum, making it techni-
cally impossible to consider liver replace-
ment. Auxiliary liver transplantation might 
be an option in such patients or in patients 
with extensive previous surgery in the right 
upper quadrant for whom orthotopic trans-
plantation would be excessively difficult or 
impossible. 
Potential Role of Liver Transplantation. A 
plan to organize a network of liver transplan-
tation centers is in the embryonal stages of 
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development. The required surgical tech-
niques are within the grasp of many practic-
ing surgeons, and the improvements in im-
munosuppression of the last few years 
should make postoperative management a 
reasonable exercise. Moreover, the number 
of bona fide candidates for this procedure per 
year will probably be in the thousands even 
if more rigid criteria of selection are imposed 
than in the past. All of these could influence 
decisions about treatment earlier in the 
course of several hepatic diseases. 
A voidance of major and often futile sur-
gical operations that can jeopardize the ulti-
mate candidacy for transplantation will be 
increasingly important. Fortunately, alterna-
tive approaches are available. Sclerosing ther-
apy for the control of variceal hemorrhages 
instead of portal diversion has become in-
creasingly accepted. Bile duct strictures in 
sclerosing cholangitis and other diseases may 
now be managed, at least palliatively, by 
non-surgical means. Better guidelines will 
need to be developed for procedures such as 
porticoenterostomy (Kasai operation) so that 
infants with biliary atresia who might benefit 
from this operation, but who could be ren-
dered non-transplantable by extensive or 
multiple and futile procedures, could be se-
lected out from those whose chances of pal-
liation are poor. 
Much new basic knowledge about the 
liver should become available as a result of 
transplantation. Information has already 
been gathered about the synthesis of 
proteins whose origin previously was not 
clear. 7 '21SR-lbO In the same context, informa-
tion is accruing about several inborn errors 
of metabolism. Rarely has such an opportu-
nity been possible to combine meaningful 
and basic scientific inquiry with the human-
itarian pursuit of improved patient care. 
Partial Hepatectomy 
The stimulus for the development of meth-
ods of partial resection of the liver was the 
referral for transplantation of many patients 
whose hepatic tumors involved most (but 
not all) of the liver. Hence, treatment of 
patients who had extensive but resectable 
lesions became a peripheral function of the 
liver transplantation service. During a 17-
year period from October 1964 to March 1982, 
150 subtotal liver resections were performed 
on our service. 161 
Work-up of Localized Hepatic Lesions. 
We have become increasingly partial to CT 
scans as the imaging procedure to help de-
cide the extent of the lesions and to plan 
how much liver must be removed. By view-
ing tomograms at different levels, a 3-dimen-
sional picture of the lesion can be con-
structed, and from this, how the mass relates 
to the anatomic segments of the liver may be 
determined. Also, cystic lesions can be dis-
tinguished from solid masses and vascularity 
revealed with adjunctive use of IV contrast 
infusion. Thus, our dependence on other 
imaging and diagnostic techniques has less-
ened and we no longer routinely obtain pre-
operative angiograms. A variant arterial 
blood supply to the liver can easily be iden-
tified at the time of operation. 
We do not recommend blind or radio-
graphically guided needle biopsy of localized 
hepatic lesions prior to surgery. Biopsies by 
referring surgeons or physicians have precip-
itated emergency operations in several of our 
patients who had hemangiomas, adenomas, 
or highly vascular malignancies. Aside from 
the risk of hemorrhage and the possibility of 
tumor spread, the small specimen obtained 
by a needle biopsy may not be adequate to 
differentiate a malignant tumor from a be-
nign one. 
Past medical history, review of operative 
records, and re-examination of previously 
obtained tissue should not be neglected prior 
to operation. Detailed history, careful physi-
cal examination, and proper use of laboratory 
tests such as the hepatitis screen and assays 
of carcinoembryonic antigen (CEA) and 
alpha-fetoprotein are often helpful in making 
a correct diagnosis. The work-up to identify 
a primary tumor of non-hepatic origin that 
may have spread to the liver or a tumor that 
may represent spread from a primary cancer 
of the liver is described in other chapters, in 
which these tumors are the subject of prime 
concern. 
Kinds of Hepatic Resections. The term 
"local excision" has been used for resections 
that do not follow intersegmental or lobar 
planes. Many benign lesions are ideally 
treated this way, since a clean plane can 
often be developed where the mass has com-
pressed adjacent liver tissue. However, the 
word "local" can be misleading because the 
masses can be enormous in size, replacing 
most of the liver. Thus, a local excision can 
be as difficult and time-consuming as a for-
mal resection. 
3424 The Liver 
The 4 anatomic resections commonly 
practiced 162 consist of removal of the true 
right lobe, the true left lobe, the lateral seg-
ment of the left lobe, and the right lobe plus 
the medial segment of the left lobe (right 
hepatic trisegmentectomy) (Fig. 176-16). 
A fifth resection has been described,163 in 
which the full left lobe plus the anterior 
segment of the right lobe is excised (left 
hepatic trisegmentectomy). With this operation, 
lesions involving predominantly the left lobe 
but extending into the anterior portion of the 
right lobe (previously considered unresect-
able) can be removed. 
The liver segmental anatomy that was the 
basis for these resections was clarified by 
Healey and Schroy,IM Goldsmith and Wood-
burne,165 and Couinaud,l66 whose studies, in 
tum, were founded on previous ones by 
American and European workers.167.168 Mc-
Indoe and Counsellerl67 first showed that the 
division between the true right and left lobes 
of the liver is not at the falciform ligament, 
but rather at a line going through the bed of 
the gallbladder and projecting posteriorly to-
ward the venae cavae (Fig. 176-16). Each 
lobe is further divided into 2 segments: the 
right lobe into anterior and posterior seg-
ments and the left lobe into lateral and medial 
segments. The branches of the portal vein, 
hepatic artery, and bile duct conform to this 
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Figure 176--16. The 4 usual kinds of partial hepatec' 
tomy. A fifth resection, left trisegmentectomy, involves 
removal of the true left lobe plus the anterior segment 
of the right lobe. (From Starzl TE et al. Surg Gynecol 
Obstet 1975; 141:.37. Reproduced with permission.) 
segmental organization. Many of the ramifi-
cations of the larger hepatic veins are distrib-
uted between rather than within segments 
and lobes. 
All of the major hepatic resections, except 
left trisegmentectomy,163 were actually per-
formed before the segmental and lobar anat-
omy was understood. Because of this, accu-
rately establishing priority for the first right 
or left lobectomy and left lateral segmentec-
tomy has not been possible.169 Right triseg-
men tecto my was first performed more than 
30 years ago by Wangensteen, 170 Lortat-Jacob 
and Robert,171 and Quattlebaum,172 but its 
forbidding mortality prevented wide use. In 
1975, we described in detail a safe technique 
of right trisegmentectomyl62 and demon-
strated its relation to other resections. A 
modification of the original technique was 
later reported that has been particularly use-
ful for bulky superior and posterior hepatic 
tumors, including those that invade the dia-
phragm. m 
With any of these resections, bleeding at 
the site of parenchymal transection' can be 
severe. If so, the porta hepatis can be tem-
porarily cross-clamped (the Pringle maneu-
ver). Huguet and co-workers174 reported that 
normothermic ischemia of the human liver 
usually can be tolerated for more than an 
hour, far longer than the previously accepted 
15- or 20-minute time limit. 
Drainage and Other Care. The subphrenic 
space must be adequately drained after par-
tial hepatectomy. Multiple closed-system 
suction drains can be placed in the huge 
dead space, or open drainage may be per-
formed with multiple I-inch Penrose drains. 
T-tube biliary drainage is not necessary un-
less the biliary system has been injured. An 
exception is left trisegmentectomy, after 
which T-tube drainage should be instituted 
with the upper limb of the tube passing into 
the remaining posterior segmental duct; this 
duct otherwise tends to become angulated. 163 
Prophylactic antibiotics are started preop-
eratively and continued for several days. In-
traoperative correction of coagulopathy is im-
portant when transfusion of a large amount 
of blood is required. Fear of hypoglycemia 
has been overemphasized. Usually, infusion 
of a 5% glucose/electrolyte solution is suffi-
cient to maintain an adequate blood glucose 
level during and after operation. Transient 
jaundice and depression of multiple hepatic 
functions are often seen after right triseg-
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figure 176-17. Postoperative evolution after an unusually extensive right trisegmentectomy. (From Starzl TE 
et al. Am J Surg 1975; 129:587-90. Reproduced with permission.) 
mentectomy, but even after an 85% resec-
tion,175 relatively complete recovery may oc-
cur within 3 or 4 weeks (Fig. 176-17). 
Jaundice has been unusual in the other kinds 
of resections. 
Indications for Hepatic Resection. The dis-
eases for which 150 resections were carried 
out in our institutions are listed in Table 176-
5. Most of the hepatic lesions requiring par-
tial hepatectomy are represented. As shown, 
the majority were primary or metastatic ma-
lignant tumors, but 64 (43%) were histopath-
ologically benign lesions. 
Benign Lesions 
CAVERNOUS HEMANGIOMA (see Chapter 
172). Of the 32 patients who underwent re-
section for this lesion, 3 had spontaneous 
hemorrhage and 2 more had emergency re-
section for bleeding after unwise needle biop-
sies. The others had significant complaints 
related to the tumor, including pain, pressure 
symptoms, and early satiety with weight 
loss. Most of the tumors were large and 
qualified for the term "giant cavernous he-
mangioma" introduced by Adam et al., 176 in 
that they were at least 4 cm in diameter. The 
majority of the hemangiomas could be ex-
cised locally, but 18 required anatomic re-
moval of a segment, lobe, or (in 6 cases) 3 
segments, all without mortality. 
Cavernous hemangiomas are the most 
common benign neoplasms of the liver, In 
(Chapter 172) and judgment is important in 
recommending their removal. Most are 
asymptomatic and are found incidentally 
during investigation or at operation for other 
conditions. We have recommended that most 
asymptomatic cavernous hemangiomas be 
observed, provided the diagnosis is certain l78; 
CT scans with contrast injection and arteri-
ography can give such assurance with almost 
total accuracy.179.I80 Failure to assess pre-
sumed hemangiomas completely can lead to 
tragedy. We have seen 2 lesions misdi-
agnosed as cavernous hemangiomas, one of 
which turned out to be an adrenocortical 
carcinoma and the other an angiosarcoma. 
ADENOMA. (see Chapter 172). Of the 14 
patients in our series with this type of tumor, 
11 were women of child-bearing age and 3 
were men aged 25,34, and 67 years. Most of 
the tumors were symptomatic, usually with 
pain or vague sensations of right upper quad-
rant pressure, and 5 had ruptured, necessi-
tating immediate operation because of intra-
abdominal hemorrhage. Three patients had 
multiple adenomas in all 4 segments of the 
3426 The Liver 
Table 176-5. INDICATIONS FOR 150 LIVER 
RESECTIONS 
Benign Diseases 
Hemangioma 
Adenoma 
Cysts: 
Disease 
Simple (4) 
Polycystic (2) 
Echinococcal (1) 
Focal nodular hyperplasia 
Trauma 
Abscess 
Fibroma 
Leiomyoma 
Regenerative nodule 
Malignant Diseases 
Primary malignant neoplasms: 
Hepatocellular carcinoma 
Squamous cell carcinoma of cyst wall 
Hepatoblastoma 
Cholangiocarcinoma 
Rhabdomyosarcoma 
Leiomyosarcoma 
Angiosarcoma 
Sarcoma, undetermined cell type 
Cholangiocarcinoma of bile duct 
Adenocarcinoma of gallbladder 
Metastatic neoplasms: 
Colorectal adenocarcinoma 
Carcinoid tumor 
Adrenocortical carcinoma 
Wilms' tumor 
Adenocarcinoma of kidney 
Spindle cell sarcoma of intestine 
Leiomyosarcoma of stomach 
Glucagonoma 
:--Jeuroblastoma of adrenal 
Melanoma of eve 
Hemangiosarcoma of breast 
Medullarv carcinoma of thyroid 
SquamOlis cell carcinoma of 
endocervix 
Ovarian carcinoma 
Total 
No. Cases 
64 cases 
32 
14 
7 
4 
3 
1 
1 
1 
1 
43 cases 
29 
3 
2 
2 
2 
1 
1 
1 
1 
1 
43 cases 
24 
3 
3 
3 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
1 
150 
liver with massive hepatomegaly and com-
plications that singly or in combination in-
cluded pain, disabling pressure symptoms, 
or hemorrhage. 
Most authorities agree that adenomas re-
quire resection in all but exceptional 
casesI81.1R4 (Chapter 172). A conservative ap-
proach carries too great a risk of rupture or 
hemorrhage and in addition the distinction 
between adenoma and minimum deviation 
hepatocellular carcinoma may be difficult. 
Anatomic hepatic resection is usually advis-
able, but smaller adenomas can be excised 
locally (Table 176--6). In the 3 patients who 
had multiple adenomas in all 4 sections of 
the liver, right trisegmentectomy was per-
formed with the expectation that the remain-
ing adenomas in the left lateral segment 
would not grow rapidly. This hope was not 
realized in 1 of the 3 patients who, within 14 
months, redeveloped the portal vein and 
inferior vena caval obstructions that had pre-
cipitated the resection. The residual lateral 
segment was removed and replaced with a 
liver homograft and the patient is well 1 year 
later. The 2 other patients whose liver rem-
nants contained adenomas are now 12 and 
20 months postoperative, respectively. 
Return of adenomas has not been seen in 
any of the patients who had single lesions. 
All of the women in this group were advised 
not to use oral contraceptive pills, although 
less than half of the women had ever been 
on oral contraceptives before the develop-
ment of adenomas. The connection between 
contraceptives and hepatic adenomas was 
made by Baum185 and confirmed by others, 
but Guzman et al. 186 questioned if the inci-
dence of these lesions has actually increased 
while conceding that their growth and pro-
pensity to hemorrhage may be related to the 
pill. 
Terblanche187 recommended a more con-
servative approach to treatment, including 
arterial embolization of the adenomas. 
Others l - 192 have recommended discontinu-
ance of oral contraceptives with subsequent 
watchful waiting, but this may be a danger-
ous management principle. 
FOCAL NODULAR HYPERPLASIA. Such lesions 
do not have a high occurrence rate of spon-
taneous hemorrhage l92 and are usually small 
and asymptomatic. They are often found 
incidentally at the time of operation or during 
diagnostic work-ups for abdominal symp-
toms. Diagnostic uncertainty may lead to 
exploratory surgery and resection. We have 
seen very large and symptomatic focal nod-
ular hyperplasias, necessitating resections of 
the magnitude of right trisegmentectomy. 
CYSTS. (see Chapter 170). The treatment of 
symptomatic non-parasitic simple cysts is still 
controversial. Some advocate that the solitary 
cysts with clear fluid be unroofed and 
drained into the peritoneal cavity and that 
cysts with bile-stained fluid be drained with 
a Roux-en-Y jejunal limb. 193 We recommend 
resection of such cysts. They can be excised 
locally or removed by anatomic resection 
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(Table 176-6). Although malignant change in 
the cyst wall is uncommon, we have treated 
3 patients who developed squamous cell car-
cinoma in the cyst wall (Table 176-6); 2 of 
the 3 were previously operated upon with 
the Roux-en-Y internal drainage technique. 
The pressure symptoms of polycystic dis-
ease of the liver can sometimes be palliated 
with multiple needle aspirations. Operative 
marsupialization, incisional drainage, or as-
piration of large cysts cannot relieve the 
symptoms better than can simple percuta-
neous needle aspirations. Therefore, opera-
tion for polycystic disease is rarely justified. 
However, occasional patients have a domi-
nance of normal tissue in the lateral segment 
of the liver. We have treated 2 such patients 
by right trisegmentectomy with prolonged 
symptomatic relief (Table 176-6). Hydatid 
cysts may be an indication for hepatic resec-
tion (see Chapter 232). 
OTHER BENIGN LESIONS. Rare benign tu-
mors, such as fibroma, rhabdomyoma, and 
leiomyoma, have been treated by hepatic re-
section. Anatomic resection is sometimes the 
best surgical procedure to control hemor-· 
rhage if severe trauma has involved an entire 
lope. 194 
Malignant Lesions (see Chapters 173, 174, 
and 175). As long as the malignant lesion is 
localized in 3 or 4 segments of the liver, 
curative subtotal hepatectomy theoretically 
can be achieved. Forty-three of the 150 pa-
tients in our hepatic resection series had 
primary malignant lesions; hepatocellular 
carcinoma was bv far the most common (Ta-
ble 176-5). Localized metastatic tumors have 
also been resected whenever possible with 
an aggressive approach particularly directed 
at metastases from primary colorectal cancers 
(Table 176-5). 
Results of Hepatic Resection 
Mortality. Any death within 30 days of 
operation or during the hospitalization for 
surgery, regardless of time, should be 
counted as an operative death. Intraoperative 
deaths have become unusual. Deaths caused 
by hepatic insufficiency are usually post-
poned for more than a month with good 
supportive therapy. The mortality of hepatic 
resection is influenced significantly by the 
indication and the underlying liver disease 
as well as the extent of the resection. 
Six of our 150 patients who underwent 
liver resection died, an operative mortality of 
4.0%. Details of the mortality after various 
kinds of resections are given in Table 176-6. 
The mortality after resection for benign and 
malignant disease was 3.1% (2 of 64) and 
4.7% (4 of 86), respectively. The circumstan-
ces of the deaths are summarized in Table 
176-7. Four of the 6 deaths were in patients 
with severe underlying liver disease (includ-
ing 3 with cirrhosis). Six of the 150 patients 
who underwent liver resection were cirrhotic 
patients. Since 3 of them died, they ac-
counted for half of our operative mortality. 
Some patients with compensated cirrhosis 
can tolerate conservative hepatic resection, 
as has been documented by Asian sur-
geons. 195-200 
The operative mortality of liver resections 
reported in the English literature since 1970 
is summarized in Table 176-8. According to 
Foster's review/OJ the operative mortality of 
liver resection for primary liver cancer was 
24% before 1970. Since then, the operative 
mortality reported from major centers has 
decreased substantially (Table 176-8). The 
operative mortality of liver resection for met-
astatic tumor may be even less. We have 
treated 43 patients with metastatic liver tu-
mor without a death in spite of the fact that 
36 of the resections were of one or more 
lobes (Table 176-6). By contrast, Morrow et 
a1. 202 reported an operative mortality of 20%. 
Anatomic resections for metastatic tumor will 
soon be performed in major centers for liver 
surgery with an operative mortality of less 
than 5%. 
Morbidity. Transient hyperbilirubinemia 
(Figure 176-17), ascites, and edema occasion-
ally develop after major hepatic resection. 
Prolonged prothrombin time and hypoalbu-
minemia may also occur (Fig. 176-17), but 
they usually are self-limited and not clinically 
significant. If the abnormal values are not 
spontaneously corrected within a week or 10 
days, surgical complications should be 
looked for. The complications encountered 
in our 150 resections (Table 176-9) are similar 
to those reported by others. 
Three of the 150 patients required re-explo-
ration for postoperative bleeding. The hem-
orrhage, which was from the raw liver sur-
face, was controlled in each case, but a 
patient whose resection was for a misdi-
agnosed giant hyperplastic nodule died sub-
sequently of hepatic insufficiency (Table 176-
7). Twelve patients had abscesses form in the 
right subphrenic space. The pus collections 
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Table 176-7. TIME AND CAUSE OF OPERATIVE MORTALITY FOLLOWING LIVER RESECTION 
Time of 
Survival 
Case Original Diagnosis Final Diagnosis Procedure (days) Cause of Death 
Hepatocellular Same RTSt 20 Hepatic failure; 
carcinoma' thrombosis of celiac axis 
2 Hepatocellular Same RTS 58 Hepatic failure; 
carcinoma in cirrhotic pulmonary metastases 
(Thorotrast) liver 
3 Infected hepatocellular Fungal and bacterial RTS 32 Hepatic failure; stress 
carcinoma abscess; thrombosis of ulcer hemorrhage 
intrahepatic portal and 
hepatic veins 
4 Hepatoma Same RTS 45 Hepatic failure; stress 
ulcer hemorrhage 
5 Hepatoma in cirrhotic Same RL:j: 0 Unrecognized perforation 
liver of central venous catheter 
into mediastinum; 
hvpovolemia and 
mediastinal tamponade 
6 Ruptured hepatocellular Giant regeneration RL Hepahc failure 
carcinoma in cirrhotic nodule in cirrhotic liver 
liver 
'Case previouslv reported.' A reversed vena caval graft had been used to drain the residual lateral segment after 
the remaining left hepatic vein had been resected. 
tRTS: right trisegmentectomy. 
tRL: right lobectomv. 
were drained in 6 instances by reopening 
prematurely closed anterior drain tracts at or 
near the body wall. Six abscesses were 
drained posteriorly by removing the right 
twelfth rib. Posterior drainage procedures 
were carried out in 6 other patients in the 
early postoperative period because of diffi-
culty in effectively irrigating deeply placed 
cavities from the anterior approach. The com-
plications occurred almost uniformly after 
right trisegmentectomy. 
Major bile leaks occurred after 2 right and 
2 left trisegmentectomies. A portion of the 
bile duct to the residual liver had been in-
volved with tumor in each instance and had 
been resected, the bile ducts being recon-
structed over a T-tube or U-tube stent. The 
bile leaks ceased spontaneously without fur-
ther operative intervention. Minor bile leaks 
through the drain were common, but these 
all closed spontaneously. Two patients de-
veloped bile duct obstruction several months 
after right trisegmentectomy in one and left 
lobectomy in the other; the 'cause was recur-
rent tumor in both cases. The obstruction 
was distal in the patient with left lobectomy 
and was relieved by anastomosing the unin-
volved proximal common duct to a Roux-en-
Y jejunal loop. 
Two patients had major stress ulcer hem-
orrhage and hepatic insufficiency after right 
trisegmentectomy. Both of these patients 
died (Table 176--7). Another patient devel-
oped a small bowel obstruction 2 weeks after 
right lobectomy, requiring lysis of the re-
sponsible adhesions. 
Survival. The 62 patients with benign dis-
ease who survived the operation were alive 
and relieved of symptoms as of October 1982 
(minimum follow-up of 6 months). Only one 
had late complications-a woman who de-
veloped hepatic adenomatosis in the residual 
left lateral segment after right trisegmentec-
tomy and who was treated with orthotopic 
liver transplantation. 
The actuarial survival of our 86 patients 
with hepatic malignancy is shown graphi-
cally in Figures 176--18 and 176--19. The 3-
year survival in patients with primary hepatic 
malignancy was 56% (Fig. 176--19), and with 
metastatic liver neoplasms the survival was 
66%. Actuarial survival :; years after liver 
resection for primary hepatic malignancy was 
46% and for metastatic neoplasms it was 
II 
II 
'I 
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Table 17&-8. OPERATIVE MORTALITY AND LONG-TERM SURVIVAL AFTER L1VI::R RESECTION 
Operative 
Survival 
Investigators Indications No. Patients Mortality" I Year 2 Years 3 Years 5 Years 
Foster" 
Lin195, 196 
Lee et a1. 197 
Joishvand 
Baiasegaram 198. 199 
Wu et a1.2OO 
AimersJo et a1. 203 
pmith~l; 
Bengmark et a1. 21,",. 210 
Longmire et a1. 1<J 
Fortner et al. Ill.:?, 206 
Adson and WeIland'" 
Wilson and Adson''''' 
Adson and 
Van Heerden"'l 
Morrow et a1. "" 
Iwatsuki et a1. ,., 
Primary liver cancer 
Metastatic tumors 
Colorectal cancer 
Primary liver cancer 
PrimarY liver cancer 
Malign'ant and benign 
All malignancy 
Primary liver carcinoma 
PrimarY liver carcinoma 
All mahgnancy 
Primary liver malignancy 
Primary liver malignancy 
Colorectal cancer 
Malignant and benign 
All malignancy 
Primary liver malignancv 
Malignant and benign 
All malignancy 
Primary liver cancer 
CoioreCtal cancer 
Colorectal cancer 
Primary liver neoplasm 
Primary liver malignancy 
Colorectal cancer 
Colorectal cancer 
Metastatic tumors 
Colorectal cancer 
Malignant and bemgn 
Malignant tumors 
Primar\' liver malignancv 
MetastatK tumors 
Metastatic colorecta! 
296 24.0'7, (A) 
Asian 24.00/, (A) 
:-.ion-Asian 22.00/, (A) 
400 
400 11.0'7, (A) 
192 
118 11.8% (8) 
165 20.0% (A) 
288 11.8% (A) 
133 12.8% (A) 
94 14.9% (A) 
181 8.8% (8) 
46 30.0% (8) 
60 6.7% (D) 
21 14.3% (A) 
32 6.3% (8) 
is 9.30/, (C) 
41 12.2'7( (C) 
19 21.2'7( (C) 
137 9.3'7, (8) 
113 10.60/, (8) 
42 167'( (B) 
43 9.3'7, (B) 
25 S.O'7( (B) 
60 6.N (B) 
46 Do/, (B) 
60 1. N (B) 
34 5.9% (B) 
64 20.0'7, (B) 
29 
150 4.00/, (A & B) 
86 4.N (A & B) 
43 9.3% (A & B) 
43 0.0'7, (A & B) 
24 0.00/, (A & B) 
33.30/, 1·100/, 
23.0% b.OC', 
59.0% 36.00/, 
44.00/, 22.0o/,t 
35.0o/d 2Ho/,t 20.0%t 19.0%t 
450%+ 300%+ 20.0%+ 20.0'7c+ 
55.9t 36.8t 38.9t 16.0'7d 
31.0SH 
26.7'7( 
47.6'7c 38.1 '7, 
20-250/,+ 
85.0'7ct+ JOl),;;' tt :Dg_lE~ tt 
870'7ctt 
88.0%t+ 48.0'7ctt 480SCtt 
65.0'7, tt 36.0'7ctt 
28 O'1ctt 
82.0%t 58.0S; t 41.0'7d 
45.0tt 34. OS; tt 
670'Ht 27.00/, tt 
77.8'7,t 59.5s";- t 55.7'7,+ 460("( + 
853'7,+ 667'.q 66. N + R;KOE~~ 
91. 3'7, + 730':;' + 73.0';,+ 52.1 ("( t 
'Definition of operative mortalit\': A = death In initial hospitalization. B = death in 30 days, C = death in 60 days, D 
intraoperative death. 
tOperat1\'c death excluded. 
tActuanal sUT\wal 
57(;.(. The difference in survival up to 5 years 
was not statistically significant between those 
with primary and metastatic liver neoplasms, 
nor were differences significant in subgroups 
of either of these 2 major categories. 
Long-term survival data have been given 
in only a handful of reports, and the most 
complete information has been for primary 
hepatic malignancy. Foster2L11 collected 296 
cases of primary liver cancer from the pre-
1970 literature; the 2- and 5-year determinant 
survival rates were 33.3% and 14% overall, 
respectively; but they were 59% and 36% for 
non-Asians as compared with 23% and 6% 
for Asian patients. Four large Asian series 
have been reported in the English literature 
since Foster's review. Lin195.1% reported 3-
and 5-vear actual survival of 20% and 190/c, 
respectively, in 1976, and Lee et al. 197 re-
ported 1- and 3-year actuarial survival of 450/c 
and 20%, respectively. Balasegaram and 
Joishy I98.1>N reported a possible survival of 
58.5% and 43.6% at 1 and 3 vears after 
resection; however, not all of their patients 
could be followed. Wu et a 1., 2(" reporting the 
largest series from a single institution in 1980, 
recorded 1- to 5-year actual survival rates of 
55.9%, 36.80/c, 28.9%, 21.8%, and 169c, re-
spectively (excluding an 8.8% operative mor-
tality). Seventy per cent of their patients had 
cirrhotic livers. Almersjo and Bengmark and 
co-workers203.2(}.j in Europe reported 2-year 
actual survival of 31 % (excluding an opera-
tive mortality of 30%), and in 1979 Smith205 
reported a 27% survival 2 years after resec-
tion. In the United States, Fortner et al. 1".200 
reported 1-, 3-, and 5-year actuarial survivals 
of 859c, 50%, and 37%, respectively (exclud-
ing the operative mortality of 16.79c). Adson 
and Weiland181 reported 3- and 5-year actu-
arial survival of 65% and 369c, respectively, 
(excluding operative deaths). Our 1- to 5-
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Table 176-9. SURGICAL COMPLICATIONS IN 
150 RESECTIONS 
Complication No. Cases 
Postoperative bleeding 
Suphrenic abscess: 
Anterior drainage 
Posterior drainage 
Subphrenic collection: 
Posterior drainage 
Major bile leak 
Bile duct obstruction due to recurrent 
tumor 
Major gastrointestinal bleeding 
Small bowel obstruction 
3 
12 
(6) 
(6) 
6 
(6) 
4 
2 
2 
year uncorrected actuarial survivals for pri-
mary malignancy are 77.8%, 59.5%, 55.7%, 
46%, and 46%, respectively. 
The results of liver resection for metastatic 
liver tumors also have been encouraging, 
particularly since such resections can be per-
formed with minimum mortality. Foster207 
reviewed the hospital records of more than 
400 patients with metastatic liver tumors 
from colorectal cancer who underwent liver 
resection, and in 1978 reported 2- and 5-year 
determinant survival of 44% and 22%, re-
spectively (excluding operative deaths). Fort-
ner et a1.182.206 reported 1-, 2-, and 3-year 
actuarial survival of 88%, 48%, and 48%, 
40 
20 
0--0 Prtmary (n o 43, 
)(-)( Metastatic (n o 43, 
2Y 3Y 4Y 5Y 
"gure 176-18. Actuarial survival after liver resection. 
Comparison between primary liver malignancies and 
metastatic liver tumors. There are no statistically slg-
nlncant differences between the 2 at any point of time. 
(from Iwatsuki Set al. Ann Surg 198.3; 197:247-5.3. 
Reproduced with permIssion.) 
Hepatoma 
0--0 Hepatoblastoma In o 321 
)(-)( Colon Ca Mets (n o 24) 
20 
l~~~--~--~--~~ 
~~ lY 2Y 3Y 4Y 5Y 
Figure 176-19. Actuarial survival after liver resection. 
Comparison between hepatomalhepatoblastoma and 
metastatic colorectal cancer. There are no statistically 
significant differences between the 2 at any point of 
time. (From lwatsuki S et al. Ann Surg 198.3; 
197:247-5.3. Reproduced with permission.) 
respectively (excluding an operative mortal-
ity of 8%). Wilson and Adson208 reported a 
5-year survival of 28% among 60 patients 
with metastases from colorectal cancer, two-
thirds of whom were treated by wedge re-
section of the liver. Later, Adson and Van 
Heerden209 reported 1-, 2-, and 3-year actual 
survival of 82%,58%, and 44%, respectively, 
among 34 patients who had major hepatic 
resections (excluding operative deaths of 
5.9%). Morrow et a1. 202 reported 1- to 5-year 
actuarial survival of 76%, 45%, 43%, 39%, 
and 34%, respectively (excluding an opera-
tive mortality of 20% ) among 64 patients with 
metastatic liver tumors; for metastatic tumors 
from colorectal cancer, they reported 2- and 
5-year actuarial survival rates of 67% and 
27%, respectively. We have obtained 1-, 3-, 
and 5-year actuarial survival of 91.3%, 73%, 
and 52.1 %, respectively, in metastatic colo-
rectal cancer without any operative mortality. 
Although our survival figures seem to be 
higher than those of others, differences be-
tween them are not statistically significant. If 
our higher survival figures hold for several 
more years, they may, at least partly, reflect 
our policy of extensive liver resections as 
opposed to local excision for metastatic tu-
mors. 
Portal-Systemic Diversion 
One of the dominant themes in the medical 
literature in the era of hepatic surgery that is 
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ending has been how portacaval and other 
portal-systemic shunts can be used to treat 
complications of portal hypertension. During 
the same time, information about the physi-
ologic effect of such procedures has accu-
mulated that has called into question the 
probity of their continued use. This new 
information, which collectively has been 
called hepatotrophic physiology,211.212 has re-
moved much of the mystery about the com-
plications and expectations after portal-sys-
temic shunting procedures. 
Hepatotrophic Physiology Before 1973. In 
1877, Eck described the operation of the com-
pletely diverting portacaval shunt in dogs. 213 
Although only one of his animals survived 
the perioperative period, Eck was convinced 
that the procedure was safe and would have 
clinical application. Only 16 years later, Pav-
lov and his assodates214 described injurious 
effects from the Eck fistula, including weight 
and hair loss, hepatic encephalopathy, and 
liver atrophy. 
Liver Changes. Three-quarters of a century 
passed before it was realized that hepatic 
atrophy caused by Eck's fistula occurs with 
astonishing rapidity, being 90% complete 
within 3 to 4 days.215,216 Electron micrographic 
techniques made it possible to develop a clear 
picture of the organelle changes caused by 
portacaval shunt in the hepatocytes of pre-
viously normal rats,217-220 dogs,215,216,221.222 sub-
human primates,222,223 and man. 224.225 The 
most striking and specific ultrastructural 
changes are depletion and disruption of 
the rough endoplasmic reticulum and reduc-
tion in the membrane-bound polyribo-
somes.m216.221-22S Other features are fattv 
liver, reduction of glycogen granules, and 
deterioration of the mitochondria. Oudea 
and Bismuth21H noted an increase in smooth 
endoplasmic reticulum in rats, but this is not 
prominent in dogs, baboons, or man. 223,2lS 
Another feature of the Eck fistula liver that 
escaped notice for a long time was a marked 
increase in hepatocyte renewal, which has 
been described in rats,219 dogs,215.216 and ba-
boons. 222,22) After portacaval shunt, the mi-
totic index and the rate of thymidine incor-
poration, as measured with autoradiography, 
rise within a few davs to a new and stable 
level 3 or 4 times higher than the preopera-
tive resting leveL The stimulus for the low-
grade hyperplasia is unknown. It may rep-
resent a response to an increased death rate 
of hepatocytes. Since hepatic hyperplasia and 
hypertrophy are parallel in most situations 
of liver regeneration, the combination of atro-
phy and hyperplasia after Eck's fistula is a 
special situation that has generated much 
discussion. 216,219 
Flow Hypothesis. Rous and Larimore226 
were intrigued with the possibilities that por-
tal venous blood contained spedal factors 
and that the extrahepatic diversion of these 
factors by portacaval shunt was responsible 
for the hepatic atrophy and the poor health 
of animals with Eck's fistula. Unfortunately, 
their experimental models did not permit 
dedsive experiments with which to support 
this suspidon. 
A contrasting hypothesis was championed 
by Mann,227 who did not believe that the 
portal blood had spedal qualities that were 
important for liver health. He envisioned the 
liver mass as a by-product of, or a kind of 
encrustation upon, its complex capillary bed, 
which in turn was controlled solely by the 
volume of blood presented to it. He wrote 
fl. • • restoration of the liver depends . . . 
upon the flow of portal blood through the 
organ and . . . the primary stimulus is the 
[quantity of] the portal blood itself" -the 
flow hypothesis. 
Studies by Child et al.,228 using portacaval 
transposition in dogs as the experimental 
model, were erroneously but generally inter-
preted as crucial evidence favoring the flow 
hypothesis and disproving the hepatotrophic 
concept. By replacing the diverted splanchnic 
venous blood with an inflow to the portal 
vein from the inferior vena cava, most of the 
adverse effects of Eck's fistula were 
avoided.228 The concept became rooted that 
the quality of portal venous blood was not a 
prime determinant of good hepatic structure, 
function, or capacity for regeneration. 228.229 
Nevertheless, the flow hypothesis did not 
satisfy everyone's curiosity. Bollman (Mann's 
associate) wrote, "In the 83 years since it was 
first reported, the Eck's fistula has been rea-
sonably successful in hiding its secrets as 
well as giving rise to many additional ques-
tions fundamental to an understanding of 
the functions of the intestine, liver, and 
brain. "230 
Hepatotrophic Concept from Studies of 
Liver Transplantation. The flow hypothesis 
was demolished by investigations that had 
their origin in studies of auxiliary liver trans-
plantation. The seminal observations,,231 were· 
that an hepatic graft transplanted as an extra 
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liver underwent rapid and remarkable atro-
phy if it was not provided with a portal 
venous inflow from the recipient splanchnic 
bed (Fig. 176-1), but that if this kind of 
splanchnic venous flow was given to the graft 
at the expense of the dog's own liver the 
atrophy now affected the native liver. 
Later, non-transplant models were devel-
oped that allowed study of the fate of liver 
fragments given different kinds of portal ve-
nous inflow but that in all other respects 
were equivalent. In one such model,232 
splanchnic venous blood was provided for 
one portal branch of the liver, whereas the 
other portal branch was supplied with blood 
from the inferior vena cava. The side receiv-
ing the high flow of vena caval input invari-
ably underwent atrophy; the atrophy could 
not be prevented even by arterializing the 
disadvantaged side. 
Hormonal Nature of Hepatotrophic 
Substances 
"Double Liver" Experiments. Another kind 
of "double liver" model was used in an effort 
to pinpoint the splanchnic organs from which 
the so-called hepatotrophic factors came. In 
this preparation, blood returning from the 
pancreas, duodenum, stomach, and spleen 
passed to one portion of the liver while the 
other liver fragment was being perfused with 
venous blood returning from the small intes-
tine (Fig. 176-20). 
The results were unequivocal. 233 The liver 
fragment perfused with blood returning from 
the upper abdominal viscera remained 
healthy. By contrast, the liver provided with 
intestinal blood became atrophic, deglyco-
genated, and fatty. The organelle structure 
of the atrophic fragment was like that after 
portacaval shunt, including disruption and 
depletion of the rough endoplasmic reticu-
lum. Such histopathologic studies in the 
splanchnic division experiments made the 
pancreas suspect as a major hepatotrophic 
source and made insulin the most likely ma-
jor hepatotrophic substance. 233 
The morphologic observations were bol-
stered in the so-called "double liver" prepa-
rations (Fig. 176-20) by numerous biochemi-
cal studies of the 2 liver sides, including 
determinations of glycogen, glucokinase, 
cyclic adenosine mono phosphate (cyclic 
AMP), active phosphorylase, and lipids. 233 
The major differences in the liver fragments 
related to the nature of the portal venous 
inflow. The details of the biochemical disas-
sociation are beyond the scope of this chap-
ter, but the reasonable inference was that the 
2 liver sides were living in different metabolic 
~@l 
B. 
c. 
PANCREATECTOMY 
figure 176-20. Splanchnic division experiments. in these dogs. the right liver lobes received venous return 
from the pancreaticogastroduodenosplenic region, and the left liver lobes received venous blood from the 
intestines. A.. Non-diabetic dogs. B, Alloxan-induced diabetic dogs. C, Dogs with total pancreatectomy. (From 
Starzl TE et aL Surg Gynecol Obstet 1975; 140:549-62. Reproduced with permission,) 
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worlds in which hormone control was the 
dominant factor. 
The nature of the biochemical differences 
suggested that endogenous insulin, which 
was being efficiently extracted by the first 
liver tissue to which it was exposed, played 
the most important role. The significance of 
endogenous insulin was further highlighted 
when the advantages enjoyed by the lobes 
perfused by splanchnic venous blood were 
greatly reduced, although not eliminated, by 
either total pancreatectomy or alloxan diabe-
tes. 222 ,234,235 While emphasizing the role of 
insulin, these investigations showed equally 
clearly that non-pancreatic hormones or 
other substances also contributed to the total 
hepatotrophic effect of splanchnic venous 
blood. Although the influence of these extra-
pancreatic factors remains unchallenged, 
they have not been identified. 
Complicated though they were, the double 
liver fragment models were crucial to an 
understanding of the enigmatic Eck fistula. 
If insulin was a vital hepatotrophic factor, 
the reason for its unmasking by the double 
liver fragment experiments became under-
standable. The well-known efficiency of in-
sulin removal during a first pass through 
hepatic tissue236 made the insulin relatively 
unavailable for a second liver or a liver frag-
ment and thus exaggerated the effect of por-
tal blood deprivation in the disadvantaged 
hepatic tissue. 
Body 
wall 
At the same time, the protection afforded 
after portal diversion by flow augmentation 
procedures, such as Child's portacaval 
transposition228 or Fisher's portal arterializa-
tion,229 was explained. If insulin and other 
hepatotrophic substances were bypassed 
around a single liver, they would be returned 
to it in a diluted form in direct relation to the 
total hepatic blood flow, which these proce-
dures increased. 
Hormone Infusion Experiments. We sus-
pected by this time that the secrets of Eck's 
fistula were explained mainly by the liver's 
being deprived of direct access to endoge-
nous insulin. The experiment shown in Fig-
ure 176-21 was designed as a direct test of 
that hypothesis. Non-hypoglycemic infu-
sions of insulin, glucagon, and other sub-
stances were made for 4 days into the ligated 
left portal vein after Eck's fistula.215,216 The 
experiment was designed to evaluate any 
direct protective effect of hormones on the 
left lobar hepatic tissue, as well as to assess 
a spillover effect on the right lobes after 
recirculation. The results were unequivocal: 
insulin greatly reduced the atrophy that oth-
erwise halved the size of the cells within 4 
days, and it preserved the hepatocyte ultra-
structurally, Glucagon in small doses did not 
potentiate the action of insulin, and in large 
doses it may have reduced the insulin bene-
fit Glucagon alone in large or small doses 
had no effect 215,216 
Pump 
figure 176-21. Experiments in which 
Eck's fistula is performed and postoper-
ative infusions are made into the left 
portal vein. (From StaTZ I TE et al. Lancet 
1976; 1:281-5. Reproduced with permis-
sion.) 
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The effect of insulin on hepatocytic prolif-
eration in these experiments was also strik-
ing. After Eck's fistula, the mitotic rate was 
already increased to about 3 times normal 
(from 1.6 to 4.8/1000 hepatocytes). Insulin 
more than tripled this cell renewal with no 
spillover to the contralateral lobes. Glucagon 
alone had no effect, nor did it potentiate the 
action of insulin.215,216 
Evisceration and Hepatocyte Culture Ex-
periments. The foregoing observations estab-
lished relative "hepatic insulinopenia" as the 
most important element in the liver injury of 
Eck's fistula. However, the clarity with which 
insulin has emerged as the principal portal 
hepatotrophic substance has not diminished 
interest in the search for contributory hepa-
totrophic factors. The observation that the 
insulin protection was not complete in our 
infusion experiments was interpreted as a 
reflection of ancillary substances. 215,216 Evi-
dence that multiple hepatotrophic factors ex-
ist has been uncovered with all of the exper-
imental models used by us. O1RIO1SIOOOIO~OPRIOPTIOPU 
However, the probability that control of 
hepatocytic integrity is multifactorial has not 
de-emphasized the central role of insulin in 
maintaining liver cells. This was again dem-
onstrated after removal of all non-hepatic 
splanchnic viscera including the pan-
creas. 237,238 The intraportal infusion of insulin 
alone prevented most of the atrophy and 
other structural deterioration of hepatocytes 
that otherwise occurred and preserved the 
rate of spontaneous renewal of hepatocytes 
that was otherwise depressed. The hepatic 
protection in eviscerated animals237 was sim-
ilar to that observed with intra portal insulin 
therapy after portacaval shunt.2\5,216 
Many investigators have described analo-
gous insulin effects in hepatocyte tissue cul-
ture systems. 239 The role of insulin in 
maintaining hepatocytic mitochondrial me-
tabolism has also been emphasized. 24O No 
potentiating effect of glucagon has been dem-
onstrated in any of these models. 
Function of the Portoprival Liver. The dis-
covery of the hormonal nature of the hepa-
totrophic substances has been coincident 
with, if not responsible for, better insight 
into the changes in hepatic function caused 
by portal diversion. Liver function after Eck's 
fistula, or after the better tolerated portacaval 
transposition of Child et al., 228 was long 
thought to be essentially normal, the main 
defect being inefficient clearance of ammo-
nia. 241 ,242 Only in the past 10 or 15 years have 
subtle but cumulatively massive changes in 
hepatic function caused by portal diversion 
been realized. These alterations are so sweep-
ing that an all-inclusive description undoubt-
edly would require a discussion of virtually 
every facet of hepatic physiology and metab-
olism. 
A relatively specific effect of portacaval 
shunt described earlier is the qualitative and 
quantitative loss of rough endoplasmic retic-
ulum (RER) and its lining polyribosomes. 
Since RER is the "factory" of the cell, 243,244 
many biosynthetic processes are conse-
quently reduced. 
Portacaval shunt reduces the serum con-
centration of cholesterol in animals222 and in 
man.245 This effect can be explained by the 
reduction in hepatic lipid synthesis demon-
strated in dogs,222,246 rats,247 swine/Is and ba-
boons. 246 As discussed later, data about he-
patic lipid synthesis also are available from 
patients treated by us with portacaval shunt 
for familial hypercholesterolemia. 
Bile acid synthesis is greatly reduced by 
portacaval shunt. 247,249 The hepatic urea 
(Krebs-Henseleit) cycle has been shown by 
Reichle et al. 250 to be depressed by Eck's 
fistula in rats and dogs. 
Other hepatic synthetic or metabolic proc-
esses probably follow the same pattern after 
portacaval shunt. This possibility is sup-
ported by many studies showing that porta-
caval shunt lowers the activity of the hepatic 
microsomal mixed-function oxidase sys-
tem. 251-255 In addition to illustrating the prin-
ciple of wide-ranging decline of hepatic syn-
thetic functions after portacaval shunt, these 
observations are of importance because the 
microsomal mixed-function oxidase system, 
for which multiple cytochrome P-450 and P-
448 species serve as terminal oxidases, me-
tabolizes a variety of drugs and foreign chem-
icals as well as endogenous compounds such 
as steroids and fatty acids. 
The evidence is overwhelming that the 
changes in hepatic function following Eck's 
fistula are caused mainly by depriving the 
liver of endogenous insulin. Reaven et al.2S6 
have shown that the disruption and disor-
ganization of the RER that are characteristic 
after portacaval shunt can be caused by the 
production of alloxan diabetes and can be 
reversed by treating the diabetes with insu-
lin. Similarly, Katd55 has shown that activity 
of the mixed-function oxidase system is de-
pressed in rats given alloxan diabetes in the 
same way as can be caused by portacaval 
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shunt. Pector et aJ. 202.257 have shown that the 
hepatic alterations in the mixed-function ox-
idase system are the same if the tied-off 
central portal vein is arterialized or revascu-
larized with systemic venous blood using the 
transposition technique. These latter experi-
ments showed that the mere restoration of 
the "wrong' kind of hepatic blood flow could 
not prevent the changes that are specific from 
portal diversion. 
Relevance of Animal Studies to Man. As 
already noted, the histopathologic alterations 
caused by portacaval shunt are not demon-
strably different in rats, dogs, swine, mon-
keys, baboons, and man.223 Whether the le-
thal consequences of portacaval shunt 
represented more than a species peculiarity 
of the dog was not known until about the 
early 1950s. The dearth of information began 
to end with the classic clinical articles of 
McDermott et aJ., 258.259 which were seemingly 
confirmed by Hubbard2bO a few years later. 
Unfortunately, misinterpretation of the ob-
servations in these reports actually delayed 
an understanding of the physiology of hu-
man portacaval shunt for almost 2 decades. 
The McDermott-Hubbard Artifact. Mc-
Dermott et aJ. 258,259 and Hubbard2bO each re-
ported on 2 patients who had carcinomas of 
the head of the pancreas and grossly normal 
livers, except for the findings of biliary ob-
struction. To perform a pancreaticoduode-
nectomy, resection of the portal vein was 
necessary, and in all 4 patients the end of 
the transected superior mesenteric vein was 
anastomosed to the side of the inferior vena 
cava. Within a few weeks or months, all 4 
patients developed episodic hepatic enceph-
alopathy, malnutrition, fatty liver, and hy-
poalbuminemia. When the patients died 4 to 
20 months postoperatively, none had recur-
rent tumor. The conclusions were reached 
that these were the first examples of Eck's 
fistula in man, that human patients were 
even more sensitive than dogs to the meta-
bolic complications of Eck's fistula, and that 
the ability of patients to tolerate portal diver-
sion was inversely related to the quality of 
pre-existing hepatic function. 
None of these conclusions was valid. The 
errors were caused by the failure to appreci-
ate that the operations were not pure Eck's 
fistulas. In addition to the portal diversion, 
all 4 of the patients also had removal of 
variable amounts of the pancreas. The latter 
organ was subsequently proved to be the 
single most important source of hepato-
trophiC substances. 
Species Encephalopathy Factor. The en-
cephalopathy (usually associated with weight 
loss and alopecia in experimental animals) 
that was first described in dogs has been 
variable in swine,248,261,262 severe in sub-
human primates,223.246263,264 and minor in 
rats. 265-267 Glial proliferation and central pon-
tine myelinolysis have been found in the 
brains of rats, monkeys, and baboons.223 
Fortunately, the remarkable encephalo-
pathic complications produced after the sub-
human primate operations have not been 
duplicated in human patients with previ-
ously normal livers. The human experience 
with Eck's fistula in the presence of normal 
hepatic function has been in patients with 
types 1, III, and VI glycogen storage disease 
(GSD) and familial hypercholesterolemia. 
Patients with GSD generally tolerate por-
tacaval shunt well in spite of the fact that 
their well functioning livers usually have 
significant pre-existing structural abnormali-
ties. 22w5 Of 9 patients followed by us for 4% 
to 19112 years after portal diversion, only 1 
developed hepatic insufficiency and enceph-
alopathy 8 years after portacaval shunt. This 
girl was successfully treated with orthotopic 
liver transplantation/o it was possible to take 
down the portacaval anastomosis and to use 
the portal vein to revascularize the new liver. 
None of the other patients with glycogen 
storage disease treated with portal diversion 
is known to have developed encephalopathy. 
The picture was even clearer in patie,nts 
who had portacaval shunts for familial hy-
percholesterolemia (FH). Characteristically, 
patients with this disease start with com-
pletely normal hepatic structure and func-
tion. Only 1 of our 13 patients, and none of 
the 26 others reported from other centers,2b!! 
has had overt manifestations of the Eck's 
fistula syndrome with follow-up periods of 1 
to nearly 10 years. The exception in our series 
was a 3-year-old girl who had a single epi-
sode of unconsciousness 9 months after por-
tacaval shunt at a time when her blood am-
monia level was 85 ~g/dl (normal <55). 
Encephalopathy was accepted as the diag-
nosis because no other explanation was 
found. The child is currently well on a low 
protein diet. • 
The histopathologic changes caused by 
portal diversion in the livers of the FH 
patients225,26H have been indistinguishable 
from those in animals. Blood ammonia levels, 
when measured, were always increased to or 
beyond the upper limits of normal;26R low-
grade elevations of activities of aminotrans-
ferase~ 
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ferases and alkaline phosphatase have been 
common. Although the patients have been 
clinically well and on normal diets after por-
tacaval shunt, hepatic function probably has 
been impaired. Nevertheless, their behav-
ioral and physical development has not been 
obviously affected. 
The only other use of portal diversion in 
the presence of a normal or nearly normal 
liver has been in patients with esophageal 
varices from extra-hepatic portal venous ob-
struction (presinusoidal block). The throm-
bosed portal vein in many such patients is 
replaced with a multitude of collaterals that 
are frequently so well developed that they 
have been referred to collectively as "cavern-
ous transformation." Flow in the collaterals is 
hepatopetaF69 and thus important in perfus-
ing the liver with hormone-rich splanchnic 
blood, albeit bv circuitous routes. If a sound 
portal-systemic anastomosis can be con-
structed (usually with splenorenal, cavo-mes-
enteric, or makeshift shunts), control of var-
iceal hemorrhage is almost always achieved. 
At the same time, the collateral splanchnic 
venous flow to the liver just described is 
"stolen" from the liver through the shunt. 269 
Despite this physiologic penalty, clinical 
results after technically satisfactory shunt 
procedures in patients with portal vein 
thrombosis usually have been good. 270 None 
of the 19 patients reported by Grauer and 
Schwartz270 developed hepatic failure or en-
cephalopathy after follow-up periods of as 
long as 2 decades. The observations were 
consonant with those of previous workers. 
Even more reassuring were the results ob-
tained by Alagille's group':'71 Seventy-six chil-
dren with portal obstruction had portal-sys-
temic shunts (32 central splenorenal, 32 
Marion mesocaval, 6 interposition mesoca-
val, 3 makeshift, 2 distal splenorenal, 1 por-
tacaval). Seventy of the shunts remained pat-
ent. Although blood ammonia levels were 
raised slightly, none of the patients devel-
oped encephalopathy as judged by neuro-
logic examinations and electroencephalo-
grams every 6 to 12 months and by analysis 
of academic performance. Physical growth 
was not interrupted and may have been 
accelerated. 
Nevertheless, hepatic dysfunction and en-
cephalopathy have been reportedm with or 
without portal diversion in patients with ex-
trahepatic portal block; in 2 such patients 
encephalopathy was reversed after discon-
necting the portal-systemic shunts and re-
storing hepatopetal blood flow. 269 Voorhees 
et al. 273 reported a high frequency of psycho-
logic and psychiatric perturbations that they 
suggested might be occult manifestations of 
encephalopathy after portal-systemic shunt-
ing. These latter conclusions have not been 
verified, and in patients with familial hyper-
cholesterolemia and portal thrombosis, care-
ful psychologic examinations and intelligence 
testing after shunt operations have not 
turned up anything resembling Voorhees' 
observation. 268,271 
The resistance of man to encephalopathy 
after portacaval shunt has not been explained 
satisfactorily. One possibility is that the nat-
ural diet of man is more compatible with the 
depressed hepatic function of Eck's fistula 
than that consumed bv some of the animal 
species. In various animals, the clinical man-
ifestations of hepatic encephalopathy can be 
forestalled or ameliorated with special low 
protein diets; use of the same kind of dietetic 
management in man is a logical response if 
hepatic encephalopathy occurs. 
Human Eck's Fistula Syndrome Versus Pre-
existing Hepatic Dysfunction. The Mc-
Dermott-Hubbard artifact may have been re-
sponsible for the widespread conviction that 
the risks of the Eck's fistula syndrome in 
human beings are proportionate to the qual-
ity of pre-existing hepatic function, being 
greatest with a completely normal liver. The 
rationale frequently has been that severely 
diseased livers that had already lost hepato-
petal portal flow to collaterals would not be 
much further affected by a portacaval shunt 
and that such livers would have compensa-
tory increases in hepatic artery flow. By con-
trast, the argument continued, normal or 
near normal livers that still retained signifi-
cant portal venous flow would sustain a 
major insult by abrupt diversion of this 
flow. 
Clinical experience with various shunting 
procedures in cirrhosis has been the opposite 
of the foregoing hypothesis. For 2 decades, 
the risk of most patients being considered 
for portal diversion has been stratified by the 
Child classification according to the quality 
of hepatic function. m Those with the best 
function (A category) have always had the 
best results. Those with the worst function 
(C category) have experienced the worst re-
sults, and those with a B classification have 
had intermediate clinical results, Parentheti-
cally, the A patients are the most apt to have 
residual hepatopetal flow, although the as-
sociation is too imperfect to be useful in 
predicting the outcome, 275,276 
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Complete Portal Diversion for Metabolic 
Dysfunction. End-to-side portacaval shunt 
has been performed in patients with glyco-
gen storage disease (GSD), familial hypercho-
lesterolemia (FH), and alpha-I-antitrypsin 
deficiency. In each instance, the liver damage 
and resulting changes in hepatic function 
have counteracted some of the lethal or un-
desirable metabolic features of the original 
inborn error. 
Glycogen Storage Disease (see Chapter 
168). Portal diversion for glycogen storage 
disease was first reported in 1965.277 The 
objective was to deglycogenate the liver, as 
had been observed to occur in animals, and 
to relieve the episodic hypoglycemia and 
acidosis that were dominant symptoms. The 
consequences of the procedure proved to be 
more subtle and wide ranging. The value of 
portacaval shunt for GSD was confirmed in 
several centers. 224 ,245,273-280 However, the need 
for portacaval shunt was abruptly eliminated 
in 1976 when an alternative form of treat-
ment, continuous alimentation, became 
available (see later). 
Our own experience with portal diversion 
was with 10 patients whose specific enzyme 
deficiencies were of glucose-6-phosphatase 
(type I, 6 examples), amylo-l,6-glucosidase 
(type III, 3 examples), and phosphorylase 
(type VI, 1 example). The first 2 patients had 
portacaval transposition, and the second of 
these died when the glycogen-laden liver was 
unable to transmit the vena caval flow. The 
other 9 patients survived, and 8 are still living 
after 7V2 to almost 20 years. 
Following portal diversion, most of the 
children who had pre-existing hypoglycemia 
did not have relief of this symptom or else 
the relief was not complete. Thus, night 
feedings usually had to be continued. Studies 
of plasma insulin and glucagon concentra-
tions were obtained in several of these pa-
tients. The flat peripheral insulin curves typ-
ical of type I glycogen storage disease281 
became elevated after portacaval shunt, and 
smaller increases in glucagon were noted. 245 
The glucose tolerance curves were the same 
before and after operation. Liver glycogen 
concentrations in our patients who later had 
liver biopsies were not changed, nor were 
the measures of hepatic enzyme activity. Cor-
beel et al. 279 found a striking increase of active 
glucose-6-phosphatase after portacaval shunt 
in a child with type lb GSD. Portal diversion 
was thought to have unmasked a non-func-
tional glucose-6-phosphatase by improving 
the defective transport of this enzyme across 
microsomal membranes. 
Despite failure to alter the hepatic glycogen 
concentration,224,245 liver size decreased in 
several patients, as measured with liver scan 
planimetry. Even if obvious shrinkage did 
not occur, postoperative biopsies always 
showed a diminution in the size of individual 
hepatocytes,224 similar to that produced in 
animals by portacaval shunt. 
Compared with the incomplete relief of 
hypoglycemia, all components of the hyper-
lipidemia characteristic of the type I disease 
were corrected permanently. Other metabolic 
defects also were corrected, including abnor-
mal bleeding, uric acid elevations, and ab-
normal calcium metabolism. 224,245,278-280,282 
All 10 of our patients had growth retarda-
tion before portacaval shunt. Afterwards, 
height increases, which in most cases had 
virtually ceased, occurred during the first 
postoperative year at the rate of approxi-
mately 0.5 CIn/month. The same thing has 
been described in all of the other reported 
cases. Quantitative measures of the phenom-
enal growth rate were obtained with radio-
graphic techniques. 224 Circulating somatotro-
pin in these patients was normal. 224 The 
growth spurts may have been at least part-
ly attributable to increased insulin distribu-
tion to the periphery, since insulin has been 
recognized to be a major growth hormone, 
comparable in potency to somatotropin. 
The morbidity from portacaval shunt was 
not excessive. The one patient already men-
tioned who developed hepatic encephalop-
athy 8 years after end-to-side portacaval 
shunt for type I GSD also had multiple filling 
defects in her enlarged liver, which proved 
to be adenomas at the time of transplanta-
tion. Another patient who had low levels of 
blood ammonia died during an angiographic 
procedure 5 years after portacaval shunt. She 
had advanced obstructive changes of the pul-
monary arterial circulation, similar to 
changes documented in other patients with 
type I GSD as well as in those with other 
liver diseases. 283 
Folkman et al. 280 showed that preoperative 
parenteral hyperalimentation could reduce 
the operative risk of portacaval shunt by 
normalizing pre-existing hepatomegaly, aci-
dosis, and other abnormalities, including hy-
perlipidemia. Greene et al.,284 in an extension 
of this concept, showed how continuous or 
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frequent feedings (including overnight ali-
mentation) could achieve the same objectives 
as portacaval diversion. Since then, continu-
ous alimentation has been the therapy of 
choice. 
Familial Hypercholesterolemia. Patients 
with this disease have absent or deficient cell 
membrane lipoprotein receptors,285 and thus 
a "switch-off" mechanism to control lipid 
(especially cholesterol) synthesis is not in 
place. Patients who are homozygous for the 
abnormality have serum cholesterol concen-
trations of 800 to 1000 mg/dl and, because of 
the resulting lipid deposits in the heart valves 
and coronary arteries, rarely live beyond the 
teens. 
Complete portal diversion reduces the 
serum cholesterol and low density lipopro-
tein (LDL) levels of such patients. us By mid-
1982, 13 patients with FH had been treated 
by us in this way.268 The total serum choles-
terol concentrations fell significantly in every 
patient after portacaval shunt. When meas-
ured, LDL cholesterol concentrations were 
reduced commensurately. The total choles-
terol declines were 20 to 55.4 (average 
33.8 ) and were maintained throughout the 
period of study. High density lipoprotein 
(HDL) cholesterol and triglyceride levels 
were variably affected. Tendinocutaneous 
xanthomas regressed or disappeared in every 
patient. 
The invariable and long-lasting lipid low-
ering in our 13 patients was achieved without 
serious morbidity. The physical development 
of those children who were normal before 
operation has proceeded, and the growth of 
those who were stunted before has moved 
toward normal. Emotional or intellectual de-
terioration secondary to the portal diversion 
has not occurred, although one child had an 
acute episode of encephalopathy that was 
managed with diet. 
Twenty-six additional patients have been 
treated elsewhere,268 13 at one institution in 
Johannesburg. 286 The results confirmed those 
obtained by us, with thrombosis of the shunt 
being the most common cause of failure. 
Cholesterol and LDL synthesis is greatly 
reduced after portacaval shunt,287.288 and total 
body cholesterol mass is reduced to half or 
less within 1 or 2 years after operation. 288 
Such data are compatible with the disappear-
ance of tendinocutaneous xanthomas and 
with the hope that the lethal cardiovascular 
complications can be slowed or forestalled by 
portacaval shunt. Despite this possibility, sta-
bilization of the vascular disease may be the 
best that can be hoped for with portacaval 
shunt, even in patients whose angina pecto-
ris is relieved, since the serum lipid levels 
are never restored to completely normal val-
ues. 
Alpha-l-Antitrypsin Deficiency. Patients 
with this disorder have a low level of plasma 
alpha-I-antitrypsin (an alpha globulin) and a 
high rate of occurrence of pulmonary com-
plications.289 Sharp et a1. 290 demonstrated a 
variable association of alpha-I-antitrypsin de-
ficiency with liver disease. 
The basis for the liver injury is the hepatic 
production of an abnormal alpha-I-antitryp-
sin that cannot be effectively transported out 
of the liver cells and that consequently be-
comes sequestered within the hepatocytes 
near the rough endoplasmic reticulum. Irri-
tation by the entrapped glycoprotein has 
been the postulated cause of the cirrhosis, 
portal hypertension, and hepatic failure that 
follow. 
We have performed end-to-side portacaval 
shunt in 3 children with the cirrhotic liver 
disease of alpha-I-antitrypsin deficiency. 291 
The first 2 patients had major hemorrhages 
from esophageal varices and the third had 
ascites. After follow-up periods for as long 
as 7 years, liver function in these 3 children 
has not greatly changed, although the plasma 
ammonia levels have been elevated when-
ever this measure was obtained. None of the 
patients has encephalopathy. The second 
and third children had liver biopsy at varying 
times after portacaval shunt and, after 2 or 3 
years, semiquantitative morphometric stud-
ies indicated that the amount of alpha-l-
antitrypsin entrapped in the liver had signif-
icantly decreased. 
Our assumption is that the portacaval 
shunt diminished the svnthesis of the abnor-
mal alpha-I-antitrypsin: presumably by alter-
ing the function of the rough endoplasmic 
reticulum without commensurately reducing 
the transport of this glycoprotein. With a 
better equilibrium between the production 
and the transport of the alpha-I-antitrypsin, 
its intracellular accumulation was possibly 
slowed or even reversed. 
Portal-Systemic Shunt for Complications 
of Portal Hypertension. After Whipple292 and 
Blakemore and Lord293 opened the modem 
era of portacaval shunt, portal diversion was 
widely used to treat intractable ascites and 
to stop or prevent hemorrhage from esoph-
ageal varices. Although portal diversion 
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often dries up ascites, its use for this purpose 
has been all but abandoned because of the 
mortality and morbidity (especially enceph-
alopathy) of the procedure, because better 
diuretics have made ascites easier to control, 
and because the safer peritoneal-venous 
(LeVeen-type) shunts can be used if medical 
manJ.gement of the ascites is unsuccessfuF94 
(Chapter 159). 
Portal-systemic shunts are still being used 
to control variceal bleeding, but are being 
recommended far less frequently (Chapter 
159). The incongruity of imposing the insult 
of portal diversion upon a liver that is already 
laboring under the handicap of intrinsic dis-
ease has become increasingly appreciated. 
Furthermore, the results of randomized clin-
ical trials in patients with or without previous 
variceal hemorrhage have not demonstrated 
a statistically significant increase in survival 
after any kind of portacaval shunt when 
compared with that achievable without op-
eration. The usual outcome after shunting 
has been that a decreased mortality after 
gastrointestinal hemorrhage has been re-
placed by perioperative deaths or by a sub-
sequent higher death rate from hepatic fail-
ure. As a consequence, alternative methods 
(such as sclerotherapy295,2% and transhepatic 
embolization of the left gastric (coronary) 
vein297) to control variceal bleeding non-
operatively without changing the pre-exist-
ing blood flow patterns have been viewed 
with increasing acceptance. 
A few patients may continue to be bona fide 
candidates for portal-systemic shunts. The 
techniques from which a choice can be made 
are shown in Figure 176--22. The literature 
about the various shunt operations is so 
voluminous and so frequently contradictory 
that no effort can be made to review it here. 
The interested reader can quickly obtain a 
good idea of what has been written by refer-
ring to Chapter 159 and by perusing one of 
several reviews. 298-300 
Portal Flow Studies in Shunt Planning. A 
logical decision about the type of shunt to be 
used cannot be reached without knowing if 
perfusion of the liver by portal blood (hepa-
tope tal flow) persists. Rough estimates of 
residual portal flow can be made with angio-
graphic techniques, including late phase ven-
ograms after selective arteriography. 301 Alter-
natively, a radiopaque dye can be injected 
directly into the portal vein by way of the 
live~O or by umbilical venography.303 
Completely Diverting Shunts. By defini-
tion, an end-to-side portacaval shunt pro-
vides absolute assurance of complete portal 
diversion. With the reduction of pressure in 
the splanchnic venous system, hemorrhage 
from esophageal varices is practically elimi-
nated, and this with an operation that can 
usually be done quickly, easily, and with 
little blood loss. Encephalopathy is a very 
common complication. 
For a long time the various side-to-side 
shunts (portacaval, cavomesenteric, mesoca-
val, or conventional splenorenal) were as-
sumed to permit partial continued perfusion 
of the liver with portal blood. However, all 
effective side-to-side shunts are merely var-
iants of the common theme shown in Figure 
176--22 (middle). All of the blood returning 
from the distal splanchnic bed is diverted 
around the liver if the anastomoses are ade-
quate. In addition, a variable amount of 
blood from the sinusoids of the liver itself 
can pass into the systemic venous circulation 
by so-called retrograde drainage. The com-
plications of hepatic failure, including en-
cephalopathy, after the various side-to-side 
shunts have been as common in controlled 
series as after end-to-side portacaval 
shunts. 304-306 The mesocaval H-graft op-
eration307 is no exception, and in addition the 
prosthesis used in this procedure has a high 
rate of late thrombosis. 308 
Selective Portal-Systemic Shunts. If the ob-
jective is to prevent recurrent hemorrhage 
from esophageal varices, a decision to per-
form a selective portal-systemic shunt should 
be bevond criticism. The selective diversion 
procedures that have been used clinically 
include the original Warren-Zeppa-Foman 
distal splenorenal shunt-'lO'! (Fig. 176--22, bot-
tom), an uncommonly performed modifica-
tion also described by Warren et al. 310 
whereby the distal splenic vein is anasto-
mosed to the inferior vena cava (Fig. 176--
22), and the direct anastomosis of the coro-
nary vein (left gastric vein) to the inferior 
vena cava described by Inokuchi et al. 311 (Fig. 
176--22). The selective shunts are technically 
more difficult and demanding than the con-
ventional completely diverting portacaval 
shunt. Yet, if it can be accomplished, a distal 
splenorenal type procedure effectively de-
compresses esophageal varices while main-
taining hepatopetal portal venous flow. War-
ren's selective procedure is associated with 
better preservation of hepatic biosynthetic 
processes such as urea production312 than 
after completely diverting portacaval shunt, 
and it carries a far lower rate of encephalop-
athy.298,313-317 
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FIgure 176-22. Kinds of portal· 
systemic shunts. A End-to-side B 
portacaval shunt. B, Variant to 
side-Io-side shunts. C, Selective 
portal-systemic shunts. 
c 
/ 
Randomized trials comparing the distal 
splenorenal shunt with totally diverting 
shunts have not revealed a striking diver-
gence in the life survival curves.298.313-317 If 
this trend continues, maintenance of a better 
quality of life, including relative freedom 
from hepatic encephalopathy, may be the 
only justification for the selective shunts in 
preference to the completely diverting 
shunts. If selective shunt procedures fail to 
provide a better life survival than totally 
diverting portacaval shunts, the most fun-
damental reason undoubtedly is that the pa-
tients under treatment have progressive he-
patic diseases with such an immutable course 
that the effect of therapeutic intervention 
cannot be accurately measured. Other factors 
may playa minor role in masking the supe-
riority of selective shunts, including a higher 
perioperative mortality while surgeons are 
learning how to carry out the Warren proce-
dure. 
I ""Dy~ 
I~1t~ 
~~ 
-
At least in some patients, the residual 
hepatopetal portal flow that is expected from 
the Warren procedure is gradually "stolen" 
from the liver as blood from the high pres-
sure mesenteric bed is recruited into the low 
pressure area drained by the distal spleno-
renal shunt. m.31S-320 The loss of portal hepatic 
perfusion is so gradual after distal spleno-
renal shunt;J13.321 that time (months or years) 
exists for compensatory physiologic adjust-
ments such as augmentation of the hepatic 
arterial input. 
The Concept of Portal Arterialization. 
After completely diverting portacaval anas-
tomosis, the possibility of replacing the lost 
portal flow with arterial blood has been ex-
amined in many experimental laboratories. 
Clinical trials have been under way in one 
American322 and one European center. 3D 
Such operations could have a minor benefi-
cial effect, since the hepatotrophic constitu-
ents that are diverted around the liver with 
.3442 The Liver 
a shunt become available in diluted form by 
way of the arterial system. These diluted 
hepatotrophic substances would be brought 
to the liver in direct relation to the quantity 
of hepatic flow. Nevertheless, any benefit 
from such flow augmentation procedures is 
limited. The atrophic changes in liver frag-
ments deprived of splanchnic venous inflow 
could not be prevented by arterializing the 
liver tissue despite flow augmentation to sev-
eral times normal volume.232 Furthermore, 
the depressed activity of the mixed function 
oxidase system following portacaval shunt 
could not be restored by rearterialization of 
the portal vein stump.257 Portal arterialization 
procedures will have little, if any, effect on 
either morbidity or mortality after completely 
diverting portal-systemic diversion. 
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